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1. INTRODUCTION 
 
              Formation and recurrence of kidney stones, one of the biggest challenges faced by 
urologists today, remains a major source of morbidity in humans. [1] This increasing 
urological disorder of human health aﬀecting about 12% of the world population has been 
associated with an increased risk of end-stage renal failure. This growing trend is believed to 
be associated with changes in lifestyle modifications such as lack of physical activity and 
dietary habits and global warming. Recurrent stone formation is a common problem with all 
types of stones and therefore an important part of the medical care of patients with stone 
disease.[2] 
In the United States, kidney stone affects 1 in 11 people, and it is estimated that 
600,000 Americans suffer from urinary stones every year. In Indian population, about 12% of 
them are expected to have urinary stones and out of which 50% may end up with loss of 
kidney functions. [3] The prevalence of urolithiasis is on the rise due to various changes in the 
socio-demographic and other etiological factors in the north-eastern states of India in general 
and Manipur in particular. [4] 
            Stone formation in the kidney is one of the oldest and most wide spread diseases 
known to man. Urinary calculi have been found in the tombs of Egyptian mummies dating 
back to 4000 BC and in the graves of North American Indians from 1500 to1000 B.C . 
Reference to Stone formation is also documented in the early Sanskrit documents during 
3000 and 2000 B.C. [5] 
               
  In general, urolithiasis affects all age groups from less than 1 year old to more than 
70, with a male to female ratio of 2:1. The peak age for the development of calcium oxalate 
stones was between 50–60 years. The risk of stone formation is generally high in men; 
however it is becoming more common in young women. Men are at greatest risk of 
developing kidney stones with incidence and prevalence rates between 2–4 times that of 
women which could be due to the larger muscle mass of men as compared to women. This 
higher rate of occurrence in men than in women can also be due to enhancing capacity of 
testosterone and inhibiting capacity of oestrogen in stone formation . Also, the increase daily 
breakdown of the tissues in men could result in increased metabolic waste and a 
predisposition to stone formation. The other more significant cause may be because of the 
male urinary tract being more complicated than the female urinary tract. Estrogen may also 
help to prevent the formation of calcium stones by keeping urine alkaline and raising 
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protective citrate levels. However, recently there are reports of dramatic increase during the 
period from 1997 to 2002 in the prevalence of stone disease among females and a change 
from a 1.7:1 to 1.3:1 male to female ratio. The increasing incidence of nephrolithiasis in 
women might be due to lifestyle associated risk factors, such as obesity.  Some reports                    
have described that vegetarians are at lower risk for stone formation in contrast to                         
non-vegetarians. [1]. 
                  
 Globally, kidney stone disease prevalence and recurrence rates are increasing, with 
limited options of eﬀective drugs. Urolithiasis aﬀects about 12% of the world population at 
some stage in their lifetime. It aﬀects all ages, sexes, and races but occurs more frequently in 
men than in women within the age of 20–49 years. If patients do not apply metaphylaxis, the 
relapsing rate of secondary stone formations is estimated to be 10–23% per year, 50% in 5–
10 years, and 75% in 20 years of the patient. However, life time recurrence rate is higher in 
males, although the incidence of nephrolithiasis is growing among females. Therefore, 
prophylactic management is of great importance to manage urolithiasis. Recent studies have 
reported that the prevalence of urolithiasis has been increasing in the past decades in both 
developed and developing countries. This growing trend is believed to be associated with 
changes in lifestyle modifications such as lack of physical activity and dietary habits and 
global warming. In the United States, kidney stone affects 1 in 11 people, and it is estimated 
that 600,000 Americans suffer from urinary stones every year. In Indian population, about 
12% of them are expected to have urinary stones and out of which 50% may end up with loss 
of kidney functions. [3] 
                   
 Studies on the geographic variation in the prevalence of kidney stone disease have 
shown a 50% higher prevalence in the southeast (the ‘kidney stone belt’) than the northwest , 
possibly associated with a changing state of dehydration related to high summertime 
temperatures and resulting in a low urine volume. Given the temperature rise worldwide due 
to the effects of global warming, it has been predicted that there could be an increase of                
1.6–2.2 million lifetime cases of kidney stone by 2050, particularly in the southeast regions 
of the USA. [6] 
                   A large number of people are suffering from urinary stone problem all over the globe. 
Not only the humans but animals and birds also suffer from the urinary stone problem. The 
occurrence in some areas is so alarming that they are known as Stone Belts .Urinary stone 
disease is a common disorder estimated to occur in approximately 12% of the population, 
with a recurrence rate of 7081% in males, and 4760% in females.  Approximately 50% of 
                                
Introduction                                                                                      
Dept of Pharmacology, Ultra College of Pharmacy.      Page 3                                     
patients with previous urinary calculi have a recurrence within 10 years. Stone disease is                
2-3 times more common in males than in females. Most urinary calculi occur in patients aged 
20 to49 years. [7]  
               
 In India, 12% of the population is expected to have urinary stones, out of which 50% 
may end up with loss of kidneys or renal damage. Also, nearly 15% of the population of 
northern India suffers from kidney stones. Fewer occurrences of urinary calculi are found in 
southern India, which may be due to regular dietary intake of tamarind. [7] 
 
KIDNEY: 
          The urinary system is the main excretory system and consists of the following 
structures, 2 kidneys, 2 ureters, urinary bladder and urethra. 
 
Definition: 
             Kidneys are a pair of excretory organs situated on the posterior abdominal wall, one 
on each side of the vertebral column, behind the peritoneum. They remove waste products of 
metabolism and excess of water and salt from the blood and maintain its PH. 
 
Location: 
            The kidneys occupy the epigastric, hypochondriac, lumbar and umbilical regions. 
Vertically they extend from the upper border of twelfth thoracic vertebra to the centre of the 
body of third lumbar vertebra. The right kidney is slightly lower than the left, and the left 
kidney is little nearer to the median plane than the right. 
The transpyloric plane passes through the upper part of the hilus of the right kidney 
and through the lower part of the hilus of the left kidney. 
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Figure No: 1 Structure of Kidney 
 
Shape, Size, Weight and Orientation:   
                 Each kidney is bean shaped. Each kidney is about 11cm long, 6cm broad, and 3cm 
thick. The left kidney is a little longer and narrower than the right kidney. On an average the 
kidney weighs 150 g in males and 135g in females. The kidneys are reddish brown in colour. 
 
ANATOMY OF KIDNEY: 
Longitudinal section of the kidney shows following parts. 
1. Capsule: It is an outermost covering composed of fibrous tissue surrounding the 
kidney. 
2. Cortex: It is a reddish-brown layer of tissue immediately below the capsule and 
outside the renal. It consists of renal corpuscles and convoluted tubules. 
3. Medulla: It is the innermost layer, consisting of conical areas called the renal 
pyramids separated by renal columns. There are 8-18 renal pyramids in each kidney. 
The apex of each pyramid is called a renal papilla, and each papilla projects into a 
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small depression, called a minor calyx (plural calyces). Several minor calyces unite to 
form a major calyx. In turn, the major calyces join to form a funnel shaped structure 
called renal pelvis that collects urine and leads to ureter. 
 
Blood supply to kidney: 
            The renal artery enters the kidney through the hilum and then branches progressively 
to form the interlobar arteries arcuate arteries, interlobular arteries, and afferent 
arterioles, which lead to the glomerular capillaries. The distal ends of the capillaries of each 
glomerulus combine to form the efferent arteriole, which leads to a second capillary network, 
the peritubular capillaries, that surrounds the renal tubules called vasa recta. The blood 
vessels of the venous system progressively form the interlobular vein, arcuate vein, interlobar 
vein, and renal vein, which leave the kidney beside the renal artery and ureter. [10],[11],[13],[14] 
 
Functions of Kidney: 
1. Endocrine functions: 
  Kidney is also endocrine glands. It secretes enzymes renin, 1, 25-
dihydroxycholecalciferol, erythropoietin etc. 
 Renin is an enzyme secreted by cells of juxtaglomerular apparatus which helps 
in regulation of blood pressure. 
 1, 25-dihydroxycholecalciferol; it is a biological active form of vitamin D3 
found in kidney.           
 Erythropoietin is essential for RBC formation. 
2. Osmoregulation: 
           Kidney regulate osmotic pressure in the body by regulating fluids and electrolyte 
balance. 
3. Homeostasis:  
       It also regulate PH balance. 
4. Excretion: 
 Metabolic wastes of the body are excreted in the form of urea, creatinine, uric 
acid etc in urine. 
 Excretion of Drugs and toxins. 
5. Selective reabsorption: 
           Glucose, amino acids, water and electrolytes etc are selectively reabsorbed in the renal 
tubules. 
                                
Introduction                                                                                      
Dept of Pharmacology, Ultra College of Pharmacy.      Page 6                                     
6. Erythropoiesis: 
           It helps in RBC formation. 
7. Blood pressure regulation. 
 8. Secretion of prostaglandins: 
The kidneys also produce prostaglandin E and prostacyclin, which have a vasodilator 
effect and are important in maintaining renal blood flow. [13],[14],[15] 
 
UROLITHIASIS:  
             The process of forming stones in the kidney, bladder, and/or urethra (urinary tract). 
 
 
Figure No: 2 Kidney Stone 
 
The development of stones is related to decreased urine volume or increased excretion 
of stone forming components such as calcium, oxalate, urate, cystine, xanthine, and 
phosphate. The stones form in the urine collecting area (the pelvis) of the kidney and may 
range in size from tiny to staghorn stones the size of the renal pelvis itself. 
The pain with kidney stones is usually of sudden onset, very severe and colicky 
(intermittent), not improved by changes in position, radiating from the back, down the flank, 
and into the groin. Nausea and vomiting are common. 
Factors predisposing to kidney stones include recent reduction in fluid intake, 
increased exercise with dehydration, medications that cause hyperuricemia (high uric acid) 
and a history of gout. 
                                
Introduction                                                                                      
Dept of Pharmacology, Ultra College of Pharmacy.      Page 7                                     
Treatment includes relief of pain, hydration and, if there is concurrent urinary 
infection, antibiotics. 
The majority of stones pass spontaneously within 48 hours. However, some stones 
may not. There are several factors which influence the ability to pass a stone. These include 
the size of the person, prior stone passage, prostate enlargement, pregnancy, and the size of 
the stone. A 4 mm stone has an 80%chance of passage while a 5 mm stone has a 20% chance. 
If a stone does not pass, certain procedures (usually by a urology specialist doctor) may be 
needed. 
The process of stone formation, urolithiasis, is also called nephrolithiasis.  
“Nephrolithiasis”  is derived from the Greek nephros-(kidney) lithos (stone) = kidney stone 
 “Urolithiasis” is from the French word “urine” which, in turn , stems from  the Latin 
“urina” and the Greek “ouron” meaning urine= urine stone. The stones themselves are also 
called renal calculi. The word “calculus” (plural: calculi) is the Latin word for                          
pebble. [12],[15],[16],[17] 
 
EPIDEMIOLOGY: 
Kidney stone disease is a multi-factorial disorder resulting from the combined 
influence of epidemiological, biochemical and genetic risk factors. Kidney stones are of four 
types. The overall probability of forming stones differ in various parts of the world and is 
estimated as 1-5% in Asia, 5-9% in Europe, 13% in North America and the recurrence rate of 
renal stones about 75% in 20 years span. It occurs both in men and women but the risk is 
generally high in men and is becoming more common in young women. [21]  
The temperature rise worldwide due to the effects of global warming, it has been 
predicted that there could be an increase of 1.6–2.2 million lifetime cases of kidney stone by 
2050, particularly in the southeast regions of the USA. [22]\ 
 
Etiology: 
Several etiological factors contribute to the pathogenesis of stone formulation. 
 Geography: 
   Kidney stone incidence varies in different parts of the world, thus projecting 
the significance of the stone belt areas. The effect of geography on the incidence of 
stone formation may be direct, through its effect on temperature, high temperatures 
increase perspiration, which may result in concentrated urine, which in turn promotes 
increased urinary crystallization. 
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 Age and Sex: 
The disease affected all age groups from less than 1 year old to more than 70, 
with a male to female ratio of 2:1. 
 Nutritional aspects: 
      An unbalanced diet or particular sensitivity to various foods in stone formers 
can lead to urinary alterations such as hypercalciuria, hyperoxaluria, hyperuricosauria, 
hypocitrauria and excessive acid urinary pH. 
 Diet : 
                      Some reports have described that vegetarians are at lower risk for stone 
formation in contrast to non-vegetarians. 
 Water intake: 
                     Supersaturation of the urinary environment with stone -forming constituents is a 
prerequisite for calculus formation and increased fluid consumption results in excretion of 
higher volume of urine, which is less supersaturated with stone -forming constituents. 
 Body weight: 
Overweight condition and obesity was found in 59.2% of the men and 43.9% of the 
women and both these conditions were strongly associated with an elevated risk of stone 
formation in both genders due to increased urinary excretion of promoters but not inhibitors 
of calcium oxalate stone formation and further concluded that overweight and obese men are 
more prone to stone formation than overweight women. 
 Kidney stone and other diseases. 
It has been proposed that essential hypertension, cardiovascular diseases (CVD), 
diabetes, and other medical conditions predispose to stone disease. 
 Recurrence: 
                     The recurrent nature of stone disease is a well-recognized Clinical problem. 
Urinary metabolic abnormalities such as low urine volume, hypercalciuria, hyperoxaluria, 
hyperuricosuria and hypocitraturia predispose a patient to early recurrence. Male gender, 
multiple stones, stone location , residual fragments  and some anatomic or functional urinary 
tract abnormalities  are known to be major risk factors for recurrence. 
 Occupation: 
                       The role of occupation in stone formation is highly debated. Kidney-related 
complications are on the increase because of geographic factors: residence in the "stone belt, 
occupation related lifestyle changes - in case of indoor occupation - sedentary habits, stress, 
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unhealthy dietary plan in terms of healthy or over healthy food intake, irregular food habits 
and fluid intake (intake of juices and beverages instead of water) or the other spectrum of 
physical manual labour-involving working outside exposed to heat and sun, low 
socioeconomic status, malnutrition and reduced fluid intake. Some experts speculated that 
this increased risk might be due to a hormone called vasopressin, which is released during 
stress, which increases the concentration of urine. 
 Molecular Aspects : 
Stone disease is a multifactorial disease; the cause of calcium oxalate stones is 
heterogeneous and might involve both genetic and environmental factors. Although extensive 
genetic studies were carried out, no chromosomal mapping has been conducted in patients 
with stones and idiopathic hypercalciuria (IH). The only conclusive evidence through genetic 
studies is that urolithiasis is a polygenic defect and partly penetrative. [21] 
 
Types of urinary calculi:  
There are 4 main types of urinary calculi-calcium containing, mixed (struvite), uric 
acid and cystine stones, and a few rare types. 
 
 
Figure No: 3 Types of Kidney Stones 
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1. CALCIUM  STONES: 
                 Calcium stones are the most common comprising about 75% of all urinary calculi. 
They may be pure stones of calcium oxalate (50%) or calcium phosphate (5%), or mixture of 
calcium oxalate and calcium phosphate (45%). 
      Etiology : 
            Etiology of calcium stones is variable. 
                  About 50% of patients with calcium stones have idiopathic hypercalciuria without 
hypercalcaemia. Approximately 10% cases are associated with hypercalcaemia and 
hypercalciuria, most commonly due to hyper parathyroidism, or a defect in the bowel (i.e. 
absorptive hypercalciuria), or in the kidney (i.e. renal hypercalciuria). 
            About 15% of patients with calcium stones have hyper uricosuria with anormal  blood 
uric acid level and without any abnormality of calcium metabolism. 
           In about 25% of patients with calcium stones, the cause is unknown as there is no 
abnormality in urinary excretion of calcium, uric acid or oxalate and is referred to as 
“idiopathic calcium stone disease”  
 
Pathogenesis: 
        The mechanism of calcium stone formation is explained on the basis of imbalance 
between the degree of supersaturation of the ions forming the stone and the concentration of 
inhibitors in the urine. Most likely site where the crystals of calcium oxalate and or calcium 
phosphate are precipitated is the tubular lining or around some fragment of debris in the 
tubule acting as nidus of the stone. The stone grows, as more and more crystals are deposited 
around the nidus. Other factors contributing to formation of calcium stones are alkaline 
urinary pH, decreased urinary volume, and increased excretion of oxalate and uric acid. 
 
Morphology : 
          Caicium stones are usually small (less than a centimetre), ovoid, hard, with granular 
surface. They are dark brown due to old blood pigments deposited in them as a result of 
repeated trauma caused to the urinary tract by these sharp edged stones. 
              
MIXED (STRUVITE) STONES: 
             About 15% of urinary calculi are made of magnesium-ammonium-calcium-hosphate, 
often called struvite; hence mixed stones are also called as ‘struvite stones’ or triple 
phosphate stones. 
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Etiology: 
            Struvite stone are formed as a result of infection of the urinary tract with urea splitting 
organisms that produce urease  such as by species of proteus and occasionally klebsiella, 
pseudomonas and enterobacter. These are, therefore, also known as infection–induced stones. 
However, E.coli does not form urease. 
 
Morphology: 
              Struvite stones are yellow white or grey. They tend to be soft and friable and 
irregular in shape. Staghorn stone which is a large solitary stone that take the shape of the 
renal pelvis where it is often formed is an example of struvite stone. 
 
URIC ACID STONE: 
                   Approximately 6% of urinary calculi are made up of uric acid. Uric acid calculi 
are radiolucent unlike radio opaque calcium stones. 
 
Etiology: 
             Uric acid stones are frequently formed in cases with hyper uricaemia and hyper 
uricosuria such as due to primary gout or secondary gout due to myeloproliferative disorders 
especially those on chemotherapy and administration of uricosuric drugs (eg salicyates, 
probenecid). Other factors contributing to their formation are acidic urinary pH (below 6) and 
low urinary volume. 
 
Pathogenesis: 
           The solubility of uric acid at pH of 7 is 200 mg/dl while at pH of 5 is 15 mg /dl. Thus 
as the urine become more acidic, the solubility of uric acid in urine decreases and 
precipitation of uric acid increases favouring the formation of uric acid stones while hyper 
uricaemia is found in half the cases. 
 
Morphology: 
   Uric acid stones are smooth, yellowish brown hard and often multiple. On cut section 
they show laminated structure. 
 
CYSTINE STONES: 
 Cystine stones comprises less than 2% of urinary calculi. 
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Etiology: 
          Cystine stones are associated with cystinuria due to genetically determined defects in 
the transport of cystine and other amino acids across the cell memebrane of the renal tubules 
and the small intestine mucosa. 
 
Pathogenesis: 
          The resultant excessive excretion of cystine which is least soluble of the naturally 
occurring aminoacids leads to the formation of crystals and eventually cystine calculi. 
 
Morphology: 
              Cystine stones are small, rounded, smooth often multiple. They are yellowish and 
waxy. 
 
OTHER CALCULI: 
 Less than 2% of urinary calculi consist of other rare types such as due to inherited 
abnormality of enzyme metabolism. E.g. hereditary xanthinuria developing xanthine               
stones. [13]  
 
Symptoms of kidney stones: 
 A kidney stone may not cause symptoms until it moves around within your 
kidney or passes into your ureter — the tube connecting the kidney and bladder. 
At that point, you may experience these signs and symptoms. 
 Severe pain in the side and back, below the ribs 
 Pain that radiates to the lower abdomen and groin 
 Pain that comes in waves and fluctuates in intensity 
 Pain on urination 
 Pink, red or brown urine 
 Cloudy or foul-smelling urine 
 Nausea and vomiting 
 Persistent need to urinate 
 Urinating more often than usual 
 Fever and chills if an infection is present 
 Urinating small amounts 
        Pain caused by a kidney stone may change — for instance, shifting to a different 
location or increasing in intensity — as the stone moves through your urinary tract. [14-19] 
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MECHANISM OF CALCIUM OXALATE RENAL STONE FORMATION:  
             The formation of renal stones is a consequence of increased urinary supersarturation 
with subsequent formation of crystalline particles. Since most of the solid particles 
crystallizing within the urinary tract will be excreted freely, particle formation is by no means 
equivalent to symptomatic stone disease. However, when solid particles are retained within 
the kidney, they can grow to become full-size stones. 
               Crystal–cell interaction is the next step, and is also promoted by renal tubular injury. 
Since crystal formation is a common phenomenon in human urine and crystalluria per sec is 
harmless, abnormal retention of formed particles must occur when kidney stones form. Thus, 
crystal–cell interactions may be highly relevant. The crystals that are internalized in the 
interstitium undergo growth and aggregation, and develop into renal stones. Each of these 
processes is described in detail below. 
 
 
                        Figure No: 4 Pathogenesis of kidney stones 
 
Using calcium oxalate stones as a model, three categories of factors (genetic, 
metabolic, and dietary) act in conjunction or in isolation to lead to kidney stone formation. 
The process probably needs an initiating nidus on the epithelium, which provides the 
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platform for crystallization and growth. The defect probably includes lesions in the cells and 
luminal factors. 
 
URINARY SUPERSATURATION AND CRYSTALLIZATION: 
               Urinary supersurturation is the driving force behind crystal formation in the 
kidneys. Since formation of crystalline particles must obviously start from supersaturation, It 
is undoubtedly essential for stone formation. Indeed, stone formers tend to excrete urine that 
is more supersaturated than that of non-stone formers. Humans normally excrete millions of 
urinary crystals daily, indicating at least transient development of supersaturation. It has been 
suggested that with a transit time across the kidney of 5–10 min, residence time is too short 
for crystals to nucleate and grow large enough to be trapped. The inner diameter of the 
various segments of the renal tubules ranges from 15 to 60 mm. Calcium oxalate crystals, 
growing at the rate of 1–2 mm/min, cannot grow larger than a few microns and are therefore 
excreted with urine without causing stone development. In tubular ﬂuid and urine, 
crystallization activity and the relative supersaturation of calcium oxalate processes are 
largely dependent on solution composition. A variety of urinary constituents may affect 
solution supersaturation because of their activity as chelaters. For instance, by forming 
soluble complexes with calcium and oxalate, respectively, citrate and magnesium reduce free 
ion. 
 
CRYSTAL NUCLEATION: 
The initial step in the transformation from a liquid to a solid phase in a supersaturated 
solution is called nucleation. This process begins with the coalescence of stone salts in 
solution into loose clusters that may increase in size by addition of new components or 
clusters. In vitro and in vivo studies have shown that renal tubular cell injury can promote 
crystallization of Calcium oxalate crystals by providing substances for their heterogeneous 
nucleation. In vitro cell degradation following renal tubular cell injury produces numerous 
membrane vesicles, which have been shown to be good nucleators of calcium crystals. In vivo 
crystals observed in the renal tubules of hyperoxaluric rats are always associated with cellular 
degradation products. 
 
CRYSTAL GROWTH: 
Once a crystal nucleus has achieved a critical size and relative supersaturation 
remains above 1, overall free energy is decreased by adding new crystal components to the 
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nucleus. This process is called crystal growth. Crystal growth is one of the prerequisites for 
particle formation and thus for stone formation. In each step of stone formation, crystal 
growth and aggregation have important functions. The crystal surface binding substance, 
which is found in Calcium oxalate crystals generated from whole human urine, is a strong 
inhibitor of Calcium oxalate crystal growth and contains human serum albumin, a1-acid 
glycoprotein, a1-microglobulin, 2-HS glycoprotein, retinol binding protein, transferrin, 
Tamm-Horsfall glycoprotein, and prothrombin. However, it has been suggested that the 
importance of crystal growth for Calcium oxalate , the most abundant stone component, is 
questionable. Since the rate of Calcium oxalate  crystal growth is low and the transit time of 
tubular ﬂuid through the kidney amounts to only several minutes, it has been calculated that 
the probability of a single particle achieving a pathophysiologically relevant size by the 
process of crystal growth alone is extremely low, even if growth proceeds at an uninhibited 
rate of 2 mm per minute. The inhibitory effect of ﬁbronectin (FN), a multifunctional 2-
glycoprotein distributed throughout the extracellular matrix and body ﬂuids, on Calcium 
oxalate crystal growth is small, considering the quantity normally excreted. ﬁbronectin at a 
concentration of 0.5 mg/mL causes only 9.9% inhibition of Calcium oxalate crystal growth. 
 
CRYSTAL AGGREGATION: 
The process whereby crystals in solution stick together to form larger particles is 
called aggregation. Some researchers have proposed that crystal aggregation is the most 
important step in stone formation. Although crystal growth is deﬁnitely a step in Calcium 
oxalate renal stone formation, the process of growth is so slow that crystals cannot become 
large enough to obstruct the renal tubules and be retained there by this mechanism alone, as 
several minutes are required for the tubular ﬂuid to pass through the kidney. For this reason, 
the more critical step is thought to be crystal aggregation. All models of Calcium oxalate 
urolithiasis concede that crystal aggregation is probably involved in crystal retention within 
the kidneys, since aggregation of crystals can have a considerable effect on particle size, and 
aggregated crystals are commonly found in urine and renal stones. 
 
             Crystal aggregation is promoted by viscous binding, implying that crystal-foreign 
compounds with multiple binding sites, such as abnormally self-aggregating Tamm-Horsfall 
glycoprotein or other macromolecules, attach to crystal surfaces and act as a kind of glue. 
The inhibitory effect of ﬁbronectin on Calcium oxalate crystal aggregation was found to be 
47.7% at the 0.5 mg/mL physiological concentration of excreted ﬁbronectin . 
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CRYSTAL CELL INTERACTION: 
                 The mechanisms of crystal–cell interaction are thought to be very complex, and 
many of them remain unexplored. Crystallization is caused by the condition of urinary 
supersaturation.  
 
Then, the crystals that have formed attach to renal tubular epithelial cells and are 
taken into them. The process of attachment or endocytosis of crystals to renal tubular cells is 
what is generally meant by crystal–cell interactions. Adhesion of 14C-labeled calcium 
oxalate monohydrate (COM) crystals was detected as early as 30 s after their addition to 
cultures of BSC-1 cells, followed by their uptake, whereas calcium phosphate crystals did not 
exhibit uptake to the same extent. The structural characteristics of the binding and uptake of 
calcium oxalate monohydrate crystals by BSC-1 cells have been characterized by scanning 
electron microscopy (SEM). Microvilli on the apical cell surface appear to make initial 
contact with the crystal before its internalization. Transmission electron microscopy (TEM) 
conﬁrmed that endocytosis of calcium oxalate monohydrate crystals by BSC-1 cells occurs as 
early as 30 min after exposure. These structural and functional studies of crystal–cell 
interactions in culture indicate that calcium oxalate monohydrate crystals rapidly adhere to 
microvilli on the cell surface and are subsequently internalized. The behavior of these cells in 
vitro provides a dynamic model to explain the presence of intracellular Calcium oxalate 
crystals in the kidneys of patients with hyperoxaluria. 
In recent years, a number of investigators have emphasized that crystal–cell 
interactions, including crystal attachment and endocytosis, are important processes in 
Calcium oxalate renal stone formation.  Crystal–cell interaction is an essential element in the 
development of urinary stone disease. Crystal–cell interactions are now thought to be  
extremely important in physiological crystal retention and the early stages of Calcium oxalate 
renal stone formation. 
        Thus, Calcium oxalate crystals may be retained in the kidney to form stones by binding 
to the apical surface of tubular cells and subsequently undergoing endocytosis. [17]  
 
 
 
 
 
                                
Introduction                                                                                      
Dept of Pharmacology, Ultra College of Pharmacy.      Page 17                                     
 
 
 
          Urinary super saturation 
                                                                                                      
                                                                                        
                        
          Crystal- Cell interaction 
 
 
 
               Crystal growth 
 
 
 
               Crystal aggregation         
 
 
 
              Stone formation 
 
 
 
 
 
 
 
Renal tubular injury 
                                
Introduction                                                                                      
Dept of Pharmacology, Ultra College of Pharmacy.      Page 18                                     
INHIBITORS: 
 
                  Inhibitors of calcium stone formation prevent crystal growth and aggregation by 
coating the surface of growing calcium crystals or by complexing with calcium and oxalate. 
 
Citrate: 
       Citric acid is a tricarboxylic acid that circulates in blood complexed to calcium, 
magnesium and sodium at physiological pH of 7.4. Most of the circulating citrate is derived 
from endogenous oxidative metabolism. It is filtered freely through the glomerulus. 
Approximately 75% of the filtered citrate is reabsorbed in the proximal convoluted tubule. 
Apart from idiopathic causes, other aetiological factors of hypocitraturia are – use of drugs 
like acetazolamide and thiazides, renal tubular acidosis, urinary tract infection, hypokalemia, 
hypomagnesemia and inflammatory bowel disease. 
 
Thiazide diuretics may induce hypocitraturia owing to hypokalemia with resultant 
intracellular acidosis. Hypocitraturia is a common disorder occurring in >50% of patients 
with nephrolithiasis. Citrate has been widely studied for its stone inhibiting action in urine 
and it has been found to be particularly effective against the calcium oxalate and phosphate 
stones. Citrate appears to alter both calcium oxalate monohydrate and calcium phosphate 
crystallisation.  
 
Pyrophosphates: 
At low concentrations, 16 mM, pyrophosphate inhibits calcium oxalate monohydrate 
crystal growth by 50%. The urinary pyrophosphate level is in the range of 20–40 mM and 
therefore, theoretically levels are high enough to inhibit Calcium oxalate and Calcium 
phosphate crystallisation. Pyrophosphate and diphosphate have shown to inhibit the 
precipitation of Calcium phosphate, where as diphosphates  also inhibits the growth of apatite 
crystals . Pyrophosphate will reduce the absorption of calcium in the intestine and this action 
probably mediated by formation of 1.25 (OH)2 – vitamin D. Sharma et al reported low 24-
hour urinary excretion of pyrophosphate in stone formers (50.672.16 mmol/24 h) as 
compared to normal subjects (71.465.46 mmol/ 24 h) (p < 0.01) . Oral administration of 
orthophosphate has shown little benefit in prevention of stone recurrence. Conversely, 
patients treated in a randomised, placebo-controlled study recorded increased stone formation 
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in the orthophosphate treated group over placebo treated subjects over a 3-year period. There 
is a lack of scientific evidence to support preventive role of orthophosphate. 
 
 Magnesium : 
           Magnesium is the fourth most abundant mineral in the body and is largely found in 
bones. Dietary magnesium is absorbed in the small intestines and excreted through the 
kidney. Only 1% of total body magnesium circulates in blood. In a supersaturated Calcium 
oxalate solution 2 mmol/L magnesium reduced particle number by 50% . Magnesium can 
form complexes with oxalate and decreases Super Saturation. Oral intake of magnesium will 
decrease the oxalate absorption and urinary excretion, in a manner similar to calcium by 
binding to oxalate in the gut. Magnesium supplementation in subjects with magnesium 
deficiency increases the excretion of citrate in urine. However, there is little evidence to 
recommend magnesium therapy in patients with urolithiasis. 
 
 Inter-alpha-trypsin inhibitor family of proteins: 
                Inter-a-inhibitor (IaI) belongs to the Kunitz-type protein superfamily, a group of 
proteins possessing a common structural element (kunin) and the ability to inhibit serine 
proteases .I aI is a glycoprotein composed of 2 heavy chains (HC1 and HC2) and one light 
chain, also known as bikunin . 
                Bikunin circulates free in plasma and is excreted in urine where it degrades 
further to fragments HI14 and HI8. Bikunin, a Kunitz type protease inhibitor found in human 
amniotic fluid and urine, exhibits anti-inflammatory and anti-metastatic functions in animals  
and humans . It is expressed mainly in the proximal tubules and the thin descending segment 
near the loop of Henle. It may contribute to the regulation of crystal adhesion and retention 
within tubules during kidney stone formation. Furthermore, the potent inhibition of Calcium 
oxalate crystal growth by these proteins, coupled with the known presence of bikunin and its 
fragments in urine, suggested the possible existence of a relationship between IaI and 
Calcium oxalate stone formation. 
 
 Osteopontin (Uropontin): 
           Osteopontin (OPN) is a negatively-charged aspartic acid rich protein that inhibits 
growth of Calcium oxalate crystals in a supersaturated solution. OPN is intimately involved 
in the regulation of both physiological and pathological mineralization. OPN is a 
phosphorylated protein of wide tissue distribution that is found in association with dystrophic 
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calcification including in the organic matrix of kidney stones. OPN is synthesised within the 
kidney and present in the human urine at levels in excess of 100 nM.  
 
 Urinary prothrombin fragment 1: 
             The blood clotting factor prothrombin is degraded into three fragments – thrombin, 
fragment 1 and fragment 2. Fragment 1 is excreted in urine and is named Urinary 
prothrombin fragment (UPTF1) and is a potent inhibitor of Calcium oxalate  stone formation 
inviter.  
          The organic matrix of Calcium oxalate crystals contains UPTF1, providing evidence 
that links the role of blood coagulation proteins with urolithiasis. UPTF1 is an important 
inhibitor of Calcium oxalate crystal aggregation and adherence of crystals to renal cells. In 
South Africa the incidence of urolithiasis in blacks is significantly less compared to whites. 
UPTF1 from the black population has a superior inhibitory activity over UPTF1 from the 
white population. Further studies indicate that saliyated glycoforms of UPTF1 afford 
protection against Calcium oxalate stone formation, possibly by coating the surface of 
Calcium oxalate crystals. 
 
Tamm-Horsfall  Protein: 
            Tammand  Horsfall  isolated a mucoprotein  from the human urine nearly 50 years 
ago, and showed that the protein was able to interact and inhibit viral haemagglutination . 
Tamm-Horsfall protein (THP), also known as uromucoid, is an 80-kDa glycoprotein 
synthesized exclusively in the thick ascending limb of the loop of Henle’sloop (TAL) with 
exception the of the macula densa. THP is the most abundant protein in the urine of normal 
mammals. THP production ranges from 30 to 60 mg/24 h in humans. 
              THP may be involved in the pathogenesis of cast nephropathy, urolithiasis, and 
tubule interstitial nephritis. There is good evidence that the excessive intake of animal protein 
predisposes to stone disease. 
              Much controversy exists about whether THP is a promoter or an inhibitor of crystal 
aggregation. Most authors believe that it is an effective inhibitor of calcium oxalate 
monohydrate crystal aggregation in solutions with high pH, low ionic strength and low 
concentration of divalent ions and THP. In contrast, with low pH, high concentrations of 
calcium, sodium, and hydrogen ions as well as low THP, inhibitory activity is lost and it may 
even become a promoter of aggregation. 
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 Glycosaminnoglycans: 
            Glycosaminnoglycans (GAGs) have been identified as one of the macromolecules 
present in the stone matrix. Chondroitin sulphate, heparin sulphate and hyaluronic acid are 
excreted in the urine. Recently, the main GAGs found in stone matrix were identified as 
heparan sulphate and hyaluronic acid. They are thought to play an important role in Calcium 
oxalate crystallization. GAGs concentration in the urine is too low to decrease calcium Super 
Saturation. In vitro, GAGs have shown to act as inhibitors of Calcium oxalate crystal growth 
and crystal aggregation. However, investigators have failed demonstrate any qualitative and/ 
or quantitative significant difference in total excretion of GAGs between stone formers and 
controls. 
 
 Renal lithostathine: 
        Lithostathine  is a protein of pancreatic secretion inhibiting calcium carbonate crystal 
growth. A protein immunologically related to lithostathine is actually present in urine of 
healthy subjects and in renal stones, renal lithostathine (RL).  Immunocytochemistry of 
kidney sections localized the protein to cells of the proximal tubules and thick ascending 
limbs of the loop of Henle. Because of its structural and functional similarities with 
pancreatic lithostathine, it was called renal lithostathine.  RL seems to control growth of 
calcium carbonate crystals. Several reports showing the presence of calcium carbonate 
(CaCO3) in renal stones suggested that crystals of CaCO3 might be present in the early steps 
of stone formation. Such crystals might therefore promote Calcium oxalate crystallization 
from supersaturated urine by providing an appropriate substrate for heterogeneous nucleation.  
 
 PROMOTERS: 
             On the cell surfaces of the kidney, cell debris, protein aggregates and other crystals 
may provide analogous site for nucleation. These nucleation sites may lower the Super 
Saturation required to initiate crystallisation and therefore promote Calcium oxalate 
crystallisation. Strong geometric similarities between the crystals of uric acid dehydrate and 
calcium oxalate monohydrate may promote over growth of one on the other, a process similar 
to the relationship between apatite and calcium oxalate monohydrate .Evidence suggests that 
uric acid and Calcium phosphate may promote heterogeneous nucleation. Another factor that 
may promote the formation and growth of intrarenal crystals is ionic calcium.  Hypercalciuria  
can decrease inhibitor function and lead to factors that modulate these crystal-cell interactions 
could stimulate the initiation of an intrarenal stone. [18] 
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DIAGNOSIS: 
             Diagnosis of kidney stones is made on the basis of information obtained from the 
history, physical examination, urinalysis, and radiographic studies. Clinical diagnosis is 
usually made on the basis of the location and severity of the pain, which is typically colicky 
in nature (comes and goes in spasmodic waves). Pain in the back occurs when calculi produce 
an obstruction in the kidney. Physical examination may reveal fever and tenderness at the 
costovertebral angle on the affected side. 
 
Imaging studies: 
           In people with a history of stones, those who are less than 50 years of age and are 
presenting with the symptoms of stones without any concerning signs do not require helical 
CT scan imaging. A CT scan is also not typically recommended in children. 
           Otherwise a noncontrast helical CT scan with 5 millimeters (0.2 in) sections is the 
diagnostic modality of choice in the radiographic evaluation of suspected nephrolithiasis. All 
stones are detectable on CT scans except very rare stones composed of certain drug residues 
in the urine, such as from indinavir. Calcium-containing stones are relatively radiodense, and 
they can often be detected by a traditional radiograph of the abdomen that includes the 
kidneys, ureters, and bladder (KUB ﬁlm). Some 60% of all renal stones are radiopaque. In 
general, calcium phosphate stones have the greatest density, followed by calcium oxalate and 
magnesium ammonium phosphate stones. Cystine calculi are only faintly radiodense, while 
uric acid stones are usually entirely radiolucent. 
       Where a CT scan is unavailable, an intravenous pyelogram may be performed to help 
conﬁrm the diagnosis of urolithiasis. This involves intravenous injection of a contrast agent 
followed by a KUB ﬁlm. Uroliths present in the kidneys, ureters, or bladder may be better 
deﬁned by the use of this contrast agent. Stones can also be detected by a retrograde 
pyelogram, where a similar contrast agent is injected directly into the distal ostium of the 
ureter (where the ureter terminates as it enters the bladder). 
      Renal ultrasonography can sometimes be useful, because it gives details about the 
presence of hydrone phrosis, suggesting that the stone is blocking the outflow of urine. 
Radiolucent stones, which do not appear on KUB, may show up on ultrasound imaging 
studies. Other advantages of renal ultrasonography include its low cost and absence of 
radiation exposure. Ultrasound imaging is useful for detecting stones in situations where             
X-rays or CT scans are discouraged, such as in children or pregnant women. Despite these 
advantages, renal ultrasonography in 2009 was not considered a substitute for noncontrast 
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helical CT scan in the initial diagnostic evaluation of urolithiasis. The main reason for this is 
that, compared with CT, renal ultrasonography more often fails to detect small stones 
(especially ureteral stones) and other serious disorders that could be causing the symptoms. 
 
Laboratory examination: 
Laboratory investigations typically carried out include: 
 microscopic examination of the urine, which may show red blood cells, bacteria, 
leukocytes, urinary casts, and crystals;  
 urine culture to identify any infecting organisms present in the urinary tract and 
sensitivity to determine the susceptibility of these organisms to speciﬁc antibiotics; 
  complete blood count, looking for neutrophilia (increased neutrophil granulocyte 
count) suggestive of bacterial infection, as seen in the setting of struvites stones . 
 renal function tests to look for abnormally high blood calcium blood levels 
(hypercalcemia);  
 24 hour urine collection to measure total daily urinary volume, magnesium, sodium, 
uric acid, calcium, citrate, oxalate, and phosphate; 
  collection of stones (by urinating through a Stone Screen kidney stone collection cup 
or a simple tea strainer) is useful. Chemical analysis of collected stones can establish 
their composition, 
                          which in turn can help to guide future preventive and therapeutic 
management.[23] 
 
Current management and treatment of Urolithiasis is aimed  in the prevention and 
treatment of recurrent urolithiasis is to increase the daily fluid intake to at least 2.5 L to 3 L 
per day  along with pain controlling drugs and medications to monitor salts that may increase 
or reduce formation of stones. On the contrary, most stones with a diameter >8 mm will 
ultimately necessitate intervention. Many allopathic agents like thiazide diuretics 
(hydrochlorothiaide), alkali (potassium citrate), allopurinol, sodium cellulose phosphate 
(SCP), penicillamine (cuprimine), analgesic (diclophenac sodium), bisphosphonates, 
potassium phosphate and probiotics (Oxalobacter formigenes) are used in treating stones. 
Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone and indapamide) produce an 
increase in tubular reabsorption of calcium, which diminishes calciuria, and hence are 
effective in reducing calciuria and stone recurrence. However, most of these standard 
pharmaceutical drugs used to prevent and cure urolithiasis are not effective in all cases, 
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costly, quite common reoccurrences, risks of long term fertility, potential side effects and no 
guarantee. [1] 
              
 A large number of Indian medicinal plants have been used in the treatment of 
urolithiasis and they have been reported to be effective with fewer side effects. 
        Before the advent of lithotripsy and ureteroscopy, most patients with symptomatic upper 
tract calculi underwent open surgical lithotomy. However, lithotripsy and ureteroscopic 
extraction have dramatically reduced the role of open stone surgery. Despite these 
advancements, techniques such as extracorporeal shock wave lithotripsy and percutaneous 
nephrostolithotomy do not assure the prevention of recurrence of the stone. They cause side 
effect such as haemorrhage, hypertension, tubular necrosis, and subsequent fibrosis of the 
kidney leading to cell injury, and ultimately recurrence of renal stone formation. Also these 
methods are costly, non-affordable by the poor section and the re-occurrence rate is also high 
(50-80%). Thus, even with the improved understanding of the mechanisms of stone formation 
and treatment, the worldwide incidence of urolithiasis is quite high and there is no truly 
satisfactory drug for treatment of renal calculi. [1],[20]   
 
       The recurrence of urolithiasis represents a serious problem, as patients who have formed 
a stone are more likely to form another, and thus stone prevention is highly recommended. 
Currently, open renal surgery for nephrolithiasis is unusual and used only rarely since the 
introduction of ESWL, which has revolutionized urological practice and almost become the 
standard procedure for eliminating kidney stones. However, in addition to the traumatic 
effects of shock waves, persistent residual stone fragments, and the possibility of infection, 
suggest that ESWL may cause acute renal injury, a decrease in renal function and an increase 
in stone recurrence. Furthermore, although some drugs used to prevent the disease have some 
positive effects, they are not effective in all patients and often have adverse effects that 
compromise their use in long-term medical treatment. Alternative treatment using 
phytotherapy has been sought; indeed, in recent years there has been a resurgence of interest 
in medicinal plants that are effective, safe and culturally acceptable. [8] 
 
 
The worldwide incidence of urolithiasis is quite high and there is no truly satisfactory 
drug for treatment of renal calculi. A large number of Indian medicinal plants have been used 
in the treatment of urolithiasis and they have been reported to be effective with fewer side 
effects. [1] 
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Many remedies have been employed during ages to treat renal stones. Most of 
remedies were taken from plants and proved to be useful, though the rational behind their use 
is not well established except for a few plants and some proprietary composite herbal drugs 
and they are reported to be effective with no side effects. The present day medical 
management of nephrolithiasis is either costly or not without side effects. Hence the search 
for antilithiatic drugs from natural sources has assumed greater importance. [9] 
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2. REVIEW OF LITERATURE 
 
 2.1 Literature review on anti urolithiatic studies: 
Sathish R et al., (2018) studied the in vitro anti-lithiatic effect of Ipomoea batatas 
(Convolvulaceae) leaves and tuberous roots. The obtained ethanolic extract of I. batatas 
leaves and tuberous roots (EIBL and EIBR) and aqueous extract of I. batatas leaves and roots 
(AIBL and AIBR) were used for this in vitro study. The dissolution method of calcium 
oxalate by titrimetry method and calcium phosphate by colorimetric method was studied. 
Nucleation and aggregation of calcium oxalate crystals were determined by a 
spectrophotometric assay. Results indicated the estimation of calcium oxalate by titrimetry 
method, the I. Batatas leaves and roots have very significant (p<0.01) capability to dissolve 
calcium oxalate. Percentage dissolution of calcium oxalate crystals was found to be 37.53%, 
22.74%, 39.74%, and 24.28% for EIBL, AIBL, EIBR, and AIBR, respectively. In the 
estimation of calcium phosphate by colorimetric method, the percentage dissolution of 
calcium phosphate crystals by EIBL, AIBL, EIBR, and AIBR was found to be 67.15%, 
43.17%, 76.74%, and 47.96%, respectively. The I. batatas leaves and roots were significantly 
(p<0.01) dissolved calcium phosphate also. The results were clearly shown that I. batatas 
extracts significantly (p<0.01) inhibited both nucleation and aggregation of calcium oxalate 
crystals by concentration-dependent manner. The maximum percent inhibition of calcium 
oxalate nucleation by EIBL, AIBL, EIBR, and AIBR was found to be 59.09%, 50.0%, 
84.09%, and 47.73%, respectively, at 1000 µg/ml.[25] 
 
Abdullah H et al., (2017) studied anti-urolithiatic of the hydroalcoholic extracts of Phoenix 
dactylifera Linn seeds (roasted and non-roasted) in calcium oxalate urolithiasis in male albino 
rats.  Lithiasis was induced by oral administration of ammonium chloride 1% and ethylene 
glycol (0.75 %v/v) in male albino rats for 28 days. The non-roasted and roasted extracts (500 
mg/kg) were administered orally from the 15th day as a curative regimen urine analysis, 
serum analysis, biochemical analysis of kidney homogenate and histopathological study were 
performed. Results indicated the urine volume, urine magnesium and kidney GSH levels 
were decreased as well as calcium excretion in urine, serum creatinine and urea, kidney MDA 
and NO contents were increased in lithiatic group as compared to control group. Treatment 
with both hydroalcoholic seed extracts restored urine volume, magnesium and kidney GSH, 
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MDA and NO levels while treatment with of non-roasted extracts reduced the elevated level 
of urinary calcium, serum creatinine and urea levels as compared to lithiatic group. 
Histopathological examination revealed tubular degeneration, dilatation, presence of CaOx 
crystals in the lumen of renal tubules and intense interstitial mononuclear cell infiltration in 
the lithiatic control group. These histopathological alterations were markedly regressed in 
other treated groups.  The results indicated that the hydroalcoholic extracts of Phoenix 
dactylifera Linn seeds either in non-roasted or roasted state have potent antiurolithiatic 
activity against calcium oxalate urolithiasis induced by ethylene glycol in male albino rats.[26] 
Chandra Shekhar Tailor et al ., (2015)  studied the, ethanolic & aqueous extracts of roots 
and rhizomes of Hedychium coronarium J. Koenig plant  were evaluated for their potential to 
dissolve experimentally prepared kidney stones like calcium oxalate by titrimetic method 
with an invitro model and Antioxidant activity performed by DPPH scavenging assay 
method. Phytoconstituents were also isolated by chromatographic techniques of this plant 
species. For performing invitro antilithiatic activity titrimetic method was adopted and for 
antioxidant activity 1, 1-diphenyl-2-picryl hydrazyl (DPPH) scavenging assay method was 
adopted. Phytoconstituents were isolated by column and thin layer chromatographic 
techniques. Results indicated the ethanolic roots & rhizomes extract of this plant produced 
highest dissolution of stones when compare to standard drug cystone and at10 mg. 
concentration. Also this study showed  alcoholic extract of roots & rhizomes of Hedychium 
coronarium J. Koenig plant  in higher concentration possess best  antioxidant  potential  as  
compare  to  standard  ascorbic acid with  IC50 value 9.0 and 18.9 µg/ml. for ascorbic acid 
and alcoholic extract respectively. Isolated phytoconstituent from alcoholic extract of this 
plant was 8a, hydroxy hedychilactone and its structure was confirmed by IR, NMR and Mass 
spectroscopic datas. [27] 
Kamil M et al ., (2015)  evaluated the effect of plant formulation ( Ziziphus spinachristi 
leaves, Alhagi maurorum roots, Zea  mays silk,   Hordeum  vulgare grains and Pimpinella  
anisum seeds) extract on kidney of Sodium oxalate induced urolithiasis in rats. The aqueous  
extract of plant formulation /standard drug cystone were administrated simultaneously at a 
dose of 100, 200 or 400 mg/kg body weight/day,  along with sodium oxalate  (70 mg/kg body 
weight/day) w/v)  for 30 days. Significant changes were observed in body weight and kidney 
weight of sodium oxalate treated rats. Histopathological results showed disrupted renal 
parenchyma showing loss of structural arrangement of renal tubules; early degenerative 
changes in glomeruli and focal calcification in glomerulo-tubular structures   were observed 
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in the renal tissue of urolithiatic rats .Cystic dilation of renal tubules with completing 
distraction of other due to necrosis with thickening of Bowman's capsules.  Hydropic 
degeneration of proximal and distal renal tubules leading narrowing its Lumenic in sodium 
oxalate treated animals.  Administration of plant formula extract or cystone along with 
sodium oxalate showed significant protective effect in body weight, kidney weight, with few 
stray areas of calcification in glomeruli and normal tubular structures, increased cellularity 
between tubules is clearly visible. Moreover, plant formula extract shows higher 
renoprotective than cystone. In conclusion, aqueous extract of the formulation of these plants 
has proved to be an effective drug in prevention of nephrolithiasis. [28] 
R Saranya et al ., (2014) studied the inhibitory potential of Beta vulgaris L. leaf and root 
aqueous extracts against calcium oxalate crystallization under in vitro condition. Under in 
vitro condition, kidney stone formation was studied using three assays such as nucleation, 
aggregation and growth. Nucleation was studied by adding calcium chloride and sodium 
oxalate solution in the presence (0.1 to 9 mg/ml) and absence of aqueous extracts at 37˚C. For 
aggregation and growth calcium oxalate monohydrate crystals were prepared and studied. 
The effect of extracts on the formation and inhibition of stone forming stages were observed 
spectrophotometrically and analyzed through phase contrast microscope at 40X 
magnification. The result obtained showed that aqueous extracts of the leaves and root of 
Beta vulgaris L. have higher capacity to inhibit the crystal nucleation, aggregation and 
growth. When compared with leaf aqueous extract, root aqueous extract of beet root showed 
better inhibitory activity. Extracts inhibited the crystallization in solution; less and smaller 
particles were observed in the presence of extracts. These results were further confirmed with 
the aggregation and growth assay, the extracts prevented the aggregation and growth of 
formed CaOx particles and it kept the crystals as dispersed. From this in vitro study we can 
conclude that beet root extract has excellent therapeutic potential as diuretic and promoting 
the inhibition of the formation of CaOx crystals. Also the phytocompounds present in this 
plant may be responsible for the anticrystallization activity. [29] 
Kumkum Agarwal et al., (2014) evaluated the Ocimum gratissimum L. has been used to 
treat various diseases including urinary stone diseases, since ancient time in India. The 
inhibition of in-vitro calcium-oxalate crystal formation by Ocimum gratissimum L. extract 
was investigated by different methods i.e. nucleation assay and synthetic urine assay. In 
nucleation assay, the aim was to evaluate the effectiveness of different concentrations of the 
extract (100-1000 mg/ml) on calcium oxalate crystallization in-vitro while in synthetic urine 
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method the percentage inhibition and growth of the calcium oxalate monohydrate crystals 
from synthetic urine at different % concentrations of extract (25-100%) was investigated. In 
both the assay % inhibition for calcium oxalate crystal formation was found directly 
proportional to the increase in concentration of the plant extract with maximum inhibition of 
66.08% at 1000 mg/ml, while in synthetic urine assay maximum inhibition was 62.07 % at 
100% concentration of extract. Thus Ocimum gratissimum L. was found to be a potent and 
promising antiurolithiatic agent, which is in accordance with its use in traditional 
medicine.[30] 
R Naga kishore et al., (2014) evaluated the effects of some traditional medicinal plants i.e., 
Brassica oleracea Gongylodes and Desmostachya bipinnata in combination and in alone on 
experimentally-induced (urolithiasis) kidney stones. Urolithiasis in animals was induced 
experimentally by administration of ethylene glycol (0.75% v/v) with ammonium chloride 
(1% w/v) in drinking water for ten days. The aqueous extract of both plants were 
administered alone and in combination to urolithiasis induced test group rats at a dose of 400 
mg/kg respectively for 10 days. After 10 days, renal function parameters measured such as 
increase in the urine urea, uric acid, and calcium and creatinine levels, which reflect the 
deposition of calcium oxalate in the kidneys.  Results indicated the serum analysis showed 
significant increase in the serum uric acid, serum creatinine, blood urea and calcium in 
urolithiasis control group rats. In addition, vehicle treated induction control group rats 
showed significant increase in the biochemical parameters.  Daily oral treatment with all most 
all extracts not significantly decreased the quantity of calcium oxalate deposited in the 
kidneys but also reverted all the biochemical changes induced by calcium oxalate 
urolithiasis.[31] 
Narendra vyas et al., (2013) evaluated the antiurolithiatic activity of ethanolic extract of 
roots (ELC 200 mg/kg) and oleanolic acid (OA 60mg/kg, O.A. 80mg /kg, O.A. 100mg/kg) 
isolated from roots of Lantana camara in albino wistar male rats using zinc disc implantation 
induced urolithiatic model. The group in which only zinc disc was implanted without any 
treatment showed increase in calcium output (23 ± 2.7mg/dL). Cystone receiving animals 
showed significant protection from such change (𝑃 < 0.01). Treatment with OA and ELC 
significantly reduced the calcium output at a dose of OA 60mg/kg (𝑃 < 0.01), OA80mg/kg (𝑃 
< 0.01), ELC 200mg/kg (𝑃 < 0.01), and OA 100mg/kg (𝑃 < 0.001), as compared with zinc 
disc implanted group. The average weight of zinc discs along with the deposited crystals in 
the only disc implanted group was found to be 111 ± 8.6mg. Group that received Cystone 
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500mg/kg showed significant reduction in the depositions (𝑃 < 0.001). Similarly, the rats 
which received OA and ELC showed reduced formation of depositions around the zinc disc 
(𝑃 < 0.001). The X-ray images of rats also showed significant effect of OA and ELC on 
urolitiasis. Thus, OA and ELC showed promising antiurolithiatic activity in dose dependant 
manner. [32] 
Ajij Ahmed et al., (2013) investigated the antiurolithiatic effect of the hydro alcoholic 
extract of Adiantum capillus veneris Linn in male Sprague Dawley rats. The effects of oral 
administration of hydro alcoholic extract of test drug were studied on calcium oxalate 
urolithiasis. A total of 48 rats were used for the study. The animals were divided into six 
groups of eight animals each. Plain control rats were treated with distilled water only, 
throughout the study period, whereas in other groups nephrolithiasis was induced by 
providing drinking water containing 0.75% ethylene glycol and 1% ammonium chloride for 7 
days. Thereafter, urine was examined for the presence of crystals. Negative control group A 
rats were sacriﬁced after 7 days, whereas negative control group B was left untreated up to 
the end of study. Test groups were treated with 127.6 mg/kg and 255.2 mg/kg of test drug and 
standard control with Cystone (750 mg/kg) for 21 days. At the end of experiment, number of 
crystals in urine and levels of calcium, phosphorus, urea and creatinine in serum were 
observed. Histopathological study of the kidney was done by light microscopy. Results 
indicated the Urine microscopy showed signiﬁcant reduction (po0.001 and po0.01) in the 
number of crystals in test groups A and B respectively. Serum levels of calcium, 
phosphorous, and blood urea were found to be decreased signiﬁcantly in all the groups. In 
both the test groups, serum creatinine level was found to be similar as in plain control. The 
animals treated with test drug showed much improvement in body weight. Histopathology of 
kidney showed almost normal kidney architecture in treated groups. The above findings 
indicated the anti urolithic activity of Adiantum capillus veneris Linn, and thus, validate the 
claims of Unani physicians for its medicinal use in urolithiasis. [33] 
Nirmala Devi R et al. (2013) studied the alternative treatment by using Aerva lanata. The 
effect of aqueous extract of dried flower of Area lanata against ethylene glycol. Induced 
renal calculi in albino wistar rats and cystone tablets in popular medicine for kidney stone 
patients. This two extracts comparative study, a renal calculus was induced in rats by 
ingesting 0.75% ethylene glycol in drinking water for 28 days and was concentrated on 
estimation of calcium, oxalate, phosphate, magnesium excretion in the urine. This elevated 
urinary calcium with high urinary oxalate might lead to calcium oxalate stone formation; 
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following administration of extracts significantly lower urinary calcium and oxalate were 
observed to compare with the cystone. This enabled us to conclude that the extract is 
antilithiatic activity. [34]  
S Kamesh waran et al., (2013) studied the Tecoma stans flowers have been preferred for 
their antiurolithiatic activity on experimentally induced urolithiatic rats. Antiurolithiatic 
activity of aqueous and methanolic extracts of Tecoma stans (AETS & METS) was carried 
out on ethylene glycol (0.75% v/v) induced urolithiasis in rats. Treatment with aqueous 
extract (200mg/kg, p.o) and methanolic extract (250mg/kg, p.o) of T.stans flowers 
significantly lowered (P<0.001) the increased levels of oxalate, calcium and phosphate in 
urine and also significantly reduced (P<0.001) their retention in kidney. The treatment with 
Aqueous extract and Alcoholic extract of Tecoma stans flowers significantly (P<0.001) 
lowered the elevated serum levels of Blood urea nitrogen, creatinine and uric acid in both 
regimens. The histopathological study of the kidney also supported the above results. The 
results were comparable to that of standard drug (Cystone). The presented data indicate that 
administration of AETS and METS to rats with experimentally-induced urolithiasis reduced 
and also prevented the formation of urinary stones, supporting folk information regarding 
antiurolithiatic activity of the plant. The reduction in the stone forming constituents in urine 
and renal tissue brought about by T.stans could contribute to its antiurolithiatic property. [35] 
D G Baheti et al., (2013) studied the effects of a polyherbal formulation (PHF) on 
experimentally-induced kidney stones. Oxalate urolithiasis in male rats was induced 
experimentally by administration of 0.75% v/v ethylene glycol with 1% w/v ammonium 
chloride in drinking water for three days followed by only 0.75% v/v ethylene glycol for 25 
days. The PHF was administered to urolithiasis induced test group rats at three doses i.e. 200, 
300 and 400mg/kg respectively for 28 days. After 28 days, highly significant deposition of 
calcium oxalate in the kidneys was noticed along with increase in the urine volume, urinary 
oxalate, calcium, levels and magnesium levels in urolithiasis control group rats as compared 
to normal group rats. The serum analysis showed significant increase in the serum uric acid, 
serum creatinine, and blood urea in urolithiasis control group rats. In addition, vehicle treated 
induction control group rats showed significant increase in the biochemical parameters such 
as ACP, ALP, AST, ALT levels and decrease in LDH levels in the kidney homogenate which 
indicated the induction of urolithiasis. Daily oral treatment with PHF at doses 300 and 
400mg/kg significantly decreased the quantity of calcium oxalate deposited in the kidneys but 
also reverted all the biochemical changes induced by calcium oxalate urolithiasis thus 
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supporting its traditional claim. 200 mg/kg dose of PHF however, was found to be 
insignificant in these regards. [36] 
NR Kachchhi et al., (2012) evaluated the antiurolithiatic activity of methanolic extract of 
Celosia argentea roots (CaME) in male albino wistar rats. Ethylene glycol (0.75% v/v in 
drinking water; 28 days) induced urolithiasis preventive model was used to study the effect of 
CaME low dose (250 mg/kg; p.o.) and high dose (500 mg/kg; p.o.). Cystone (750 mg/kg; 
p.o.) was used as a standard. At the end of the treatment changes in various physical 
parameters, promoters, inhibitors, renal function markers in urine and serum samples and 
antioxidant parameters and histopathology of kidneys were observed. Treatment groups 
significantly prevented improvement in urinary pH, diuresis and body weight. All the 
treatments significantly prevented the rise in promoters like calcium, oxalate, uric acid, and 
inorganic phosphate and increased the levels of magnesium and citrate like inhibitors in 
various biological samples. Renal function impairment and oxidative stress was also 
prevented by the treatment as observed by BUN and creatinine analysis and analysis of 
MDA, proteins, catalase and histopathology respectively. Thus methanolic extract of Celosia 
argentea roots has proved to be an effective drug in prevention of urolithiasis. [37]  
Surendra K. Paretato et al., (2011) studied the inhibitor effect of hydroalcoholic extract of 
Achyranthes indica Linn. On the crystallization of calcium oxalate in synthetic urine. Our 
study of the calcium oxalate crystallization is based on change in turbidity followed at 620nm 
by means of a spectrophotometer. The calcium oxalate formation is induced by the addition 
of 0.01M sodium oxalate solutions in synthetic urine. The addition of inhibitor with various 
concentrations (10%, 20%, and 40%) enabled us to give information on the percentage of 
inhibition. The comparison between the turbidimetric slopes with and without inhibitor gives 
the effectiveness of inhibitor for the hydroalcoholic extract. By comparing the 
photomicrographs of with and without inhibitor, we concluded that the extract of 
Achyranthes indica Linn. acts on nucleation as well as crystal growth stage. The 
hydroalcoholic extract of the Achyranthes indica Linn. remarkably inhibits of crystal 
formation in calcium oxalate urinary lithiasis. [38] 
Manabu T moriyama et al., (2009) evaluated the mechanism of Urocalun, an extract of 
Quercus salicina Blume / Quercus stenophylla Makino (QS), in the treatment of urolithiasis. 
Rat calcium oxalate urolithiasis was induced by oral administration of ethylene glycol and the 
vitamin D3 analog alfa-calcidol for 14 days. QS Extract was repeatedly given to rats. After 
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the last administration, biochemistries in urine and plasma, renal calcium, and urinary 
malondialdehyde (an oxidative stress marker) were measured. Results indicated the Ethylene 
glycol and alfa-calcidol treatment increased urinary malondialdehyde and renal calcium 
levels. This increase was signiﬁcantly suppressed by the administration of QS extract, 
suggesting that the inhibition of renal calcium accumulation by QS extract is due to its 
antioxidative activity. Conclusions: These ﬁndings suggest that the antioxidative activity of 
QS extract plays a role in the prevention of stone formation and recurrence in urolithiasis. [39] 
2.2 Literature review on various pharmacological activities of Phaseolus vulgaris Linn 
Louise Anin, Anin Atchibri et al., (2017) evaluated the hypoglycemic and lipid-lowering 
effect of the aqueous extract of Phaseolus vulgaris in rat rendered diabetic by diet. The 
effects of the nutritional supplementation of Phaseolus vulgaris, at the rates of 300 mg / Kg 
in high carbohydrate and high fat diets, diabetic Wistar rat race, for 6 weeks, were analyzed 
on several measures of glucose and lipid metabolism. The aqueous extract of bean seed 
germinated is highly effective in reducing the level of glucose in the blood of diabetic rats, 
while increasing insulin levels. The concurrent negative biochemical factors in the type 2 
diabetes, such as triglycerides, total cholesterol, and LDL cholesterol undergo a decrease, 
while the HDL cholesterol increased in diabetic rats having ingested the aqueous extract of 
bean seed. Thus, Phaseolus vulgaris is an important contribution in the formulation of 
dietetic diets, because it constitutes a useful supplement which would permit to decrease the 
dosages of oral hypoglycemic in the case of the non insulino-dependent diabetes, by giving a 
greater comfort of life to the patient, and by decreasing the importance of the side effects 
related to the anti-diabetic medications which are far from being negligible. [40] 
Salman Ahmed et al., (2016) studied all possible morphological features of calcium oxalate 
monohydrate and calcium oxalate dihydrate crystals and their habits in case of inhibition. In 
this the study was carried out on glass slide to observe the growth and inhibition of calcium 
oxalate monohydrate (COM) crystals by using infusions (5-20%) of Macrotyloma uniflorum 
(Lam.) Verdc, Phaseolus lunatus Linn. and Phaseolus vulgaris Linn. The reagent of double 
diffusion gel technique was used for this purpose.  Results indicated that the Calcium oxalate 
crystals are divided into three types, calcium oxalate monohydrate, calcium oxalate dihydrate 
and calcium oxalate trihydrate. These types are further divided into sub types on the basis of 
their morphology. In case of calcium oxalate monohydrate (COM), these crystals are donut, 
dumbbell, needles, platy, prismatic, rosette, round edges and X-shaped. Whereas, calcium 
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oxalate dihydrate (COD) are reported as the elongated large rods and tetragonal bipyramidal 
forms. In the present study dendritic or arborescent (tree like platy crystals) were observed 
for the first time as the part of a COM growth. Long chain loose agglomerates and compact 
aggregated crystals are the common pattern of calcium oxalate crystals. All tested infusions 
caused growth inhibition of calcium oxalate crystals. Smaller zones of nucleation and 
defected shape of the grown crystals; declare as different patterns of growth inhibition. 
Conclusion: This study gives an extensive information about morphology, aggregation and 
growth inhibition of calcium oxalate crystals. [41] 
Mariana Yuriivna Kyznetsova et al ., (2015) studied the social significance of diabetes 
mellitus lies in the fact that in addition to significant prevalence, this disease is associated 
with many complications. To facilitate the course of diabetes and its complications medicinal 
plants are widely used in traditional medicine. One of such plants is kidney bean (Phaseolus 
vulgaris). This plant is used in traditional medicine, especially for the secondary 
complications of diabetes. Since complications of diabetes are often associated with increased 
oxidative stress, the study of antioxidant properties of P. vulgaris is important to clarify the 
mechanism of its therapeutic effect. Present investigation shows that long-term oral 
administration of aqueous P. vulgaris pods extract in dose of 200mg/kg b.w. besides its 
pronounced hypoglycemic action also has a positive influence on the liver and kidney 
function markers in STZ-treated diabetic rats. The extract also inhibits free radical production 
and lipid peroxidation and activates antioxidant enzymes in liver and kidneys of rats with 
STZ-induced diabetes. Thus, our data reveal antioxidant properties of aqueous P. vulgaris 
pods extract that might have beneficial effect in treatment of diabetes. [42] 
M. R.  Pradeepkumar et al ., (2015) studied an objective of developing some novel 
analgesic and anti-inflammatory natural agents with fast acting and low toxicity profile 
herein, the different extracts of Phaseolus vulgaris (Linn) seeds were evaluated for analgesic 
and anti-inflammatory activities using glacial acetic acid induced writhing and carrageenan 
induced rat paw oedema method respectively. For screening of the extracts for analgesic and 
anti-inflammatory activities aspirin and diclofenac were used as standard drugs respectively. 
Petroleum ether extract exhibited significant analgesic and anti-inflammatory activities. The 
petroleum ether extract can be considered as a potential candidate for analgesic and                     
anti-inflammatory activities. The presence of steroids and flavonoids in petroleum ether 
extract of Phaseolus vulgaris Linn. seeds could be attributed for the analgesic and                         
anti-inflammatory activities. [43] 
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N. Sree Lakshmi et al., (2015) evaluated antiurolithiatic activity of ethanolic seed extract of 
Phaseolus vulgaris (EPV) on in vitro calcium oxalate (CaOx) crystallization. In vitro CaOx 
crystallization was assessed by employing crystal nucleation, aggregation and growth assay 
methods in the presence and absence of EPV at the concentration range of 100-1000 µg/ml. 
Cystone (100-1000 µg/ml) was used as positive control. Effect of EPV on the rate of crystal 
nucleation, aggregation and growth were measured spectrophotometrically and their 
percentage inhibition was calculated. Morphological characteristics of the crystals in control, 
cystone and EPV were observed under phase contrast microscope. EPV and cystone 
produced dose-dependent inhibition of crystal nucleation, aggregation and growth. IC50 
values of cystone on nucleation, aggregation and growth were found to be 166.40±22.31, 
343.69±27.51 and 360.10±17.52 μg/ml respectively, whereas with EPV, IC50 values were 
489.10±49.27, 580.11±53.16 and 725.70±29.33 μg/ml respectively. Results of the present in 
vitro study suggest that ethanolic seed extract of P. vulgaris possess calcium oxalate crystal 
inhibition activity on crystal nucleation, aggregation and growth suggesting its antiurolithiatic 
activity. [44] 
Luka CD et al., (2013) studied the aqueous extract of Phaseolus Vulgaris L. (Red Kidney 
Beans) was investigated for its effects in alloxan induced-diabetic rats. Twenty four albino 
rats were randomly allocated into four groups (A-D) of six rats each such that group A 
(diabetes control) received 0.5 mL distilled water, group B (diabetes) received 400 mg/kg 
bwt of extract, group C (normal control) received 0.5 mL of distilled water while group D 
(normal) received 400 mg/kg bwt of extract, all extract were orally administered once daily 
for 14 days. Diabetes was induced in groups A&B by single interperitonial injection of 150 
mg/kg alloxan monohydrate. Phytochemical screening indicated the presence of alkaloids, 
balsam, flavonoids, saponins, tannins, cyanogenic glycosides, terpenes and steroids. The 
hypoglyceamic potential of Phasoelus vulgaris L. was expressed in diabetes treated rats. 
Blood glucose, total protein, albumin and cholesterol levels of the diabetes treated rats and 
normal treated rats were not significantly (p>0.05) altered when compared with the control 
rats. However, these values were significantly (p<0.05) increased in diabetes untreated rats. 
Aqueous extracts of Phaseolus vulgaris L. at 400 mg/kg body weight also significantly 
reduce (p<0.05) the values of ALT, AST and ALP when compared to high values of the 
enzymes observed in diabetes untreated rats. Extract had no significant (p>0.05) effects on 
PCV and Hb in all groups when compared to the normal control. The study showed that the 
aqueous extract of Phasoelus vulgaris L. leaves possess hypoglycaemic, antidiabetic 
                                                                                                                                         Review of Literature 
Dept of Pharmacology, Ultra College of Pharmacy.  Page  36  
                                        
properties and ameliorating the high levels of marker enzymes observed in diabetes untreated 
rats. [45] 
L. Ocho-Anin Atchibri et al (2010) studied the Seeds of Phaseolus vulgaris were given 
individually at different doses to different batches of rats (both normal and hyperglicemic 
rats) after an overnight fast. Seeds contain the bioactive components – alkaloids, flavonoids, 
fiber, proteins, tannins, terpenoids, saponins, quercetin, anthocyanin and catechin. The blood 
glucose levels were measured at 0, 1, 2, 3, 4, 5 and 6 h after the treatment. Most active doses 
were further studied to dose-dependent (300, 200 and 100 g/kg bw) antihyperglycemic effects 
alone and in combination with glibenclamide (0.20, 0.10 and 0.05 g/kg bw). Seeds of P. 
vulgaris at a dosage of 300 g/kg bw is showing maximal blood glucose lowering effect in 
diabetic rats after third hour. The antihyperglycemic activity of P. vulgaris seeds was 
compared with the treatment of glibenclamide, an oral hypoglycemic agent. The combination 
of seeds of most dose (300 mg/kg bw) and higher dose of glibenclamide (0.20 g/kg bw) 
showed safer and potent hypoglycemic as well as antihyperglycemic activities without 
creating severe hypoglycemia in normal rats. [46]  
L. Pari et al (2003) studied the Oral administration of 200 mg/kg of aqueous extract of 
Phaseolus vulgaris pods (PPEt) to diabetic animals for 45 days resulted in a significant 
decrease in blood glucose, glycosylated haemoglobin and significant increase in total 
haemoglobin and plasma insulin. Similarly oral administration of PPEt to normal animals 
resulted in a significant hypoglycemic effect. The activities of hepatic hexokinase, glucose 6-
phosphatase, fructose-1, 6-bisphosphatase and glucose-6-phosphate dehydrogenase, a 
lipogenic enzyme, were measured in the liver of normal and experimental animals. The 
activities of the lipogenic enzyme and hexokinase were significantly decreased, whereas the 
activities of gluconeogenic enzymes were significantly increased in the diabetic liver. Both 
PPEt and glibenclamide reversed the activities of these enzymes to near normal levels. PPEt 
was more effective than glibenclamide. The results indicate that the administration of PPEt to 
diabetic animals normalizes blood glucose and causes a marked improvement of altered 
carbohydrate metabolic enzymes during diabetes. [47] 
L Hangen et al., (2002) investigated (Phaseolus vulgaris) an important food staple in many 
traditional diets. There is limited evidence to suggest an inverse relationship between bean 
consumption and colon cancer. The objective of this study was to determine whether 
consumption of black beans and/or navy beans would reduce colon carcinogenesis in rats. 
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Rats were fed a modified AIN-93G diet (control) or diets containing 75% black beans or 75% 
navy beans for 4 wk, and then colon cancer was initiated by administration of two injections 
of azoxy methane1 wk apart. At 31 wk after these injection, the incidence of colon adeno 
carcinomas was significantly lower (P < 0.05) in rats fed the black bean (9%) and navy bean 
(14%) diets than in rats fed the control diet (36%). Total tumor multiplicity was also 
significantly lower in rats fed the black bean (1.1) and navy bean (1.0) diets than in rats fed 
the control diet (2.2). The 44–75% reduction in colon carcinogenesis in rats fed beans was 
attributed to 1) more controlled appetites, leading to significantly less body fat, and 2) much 
greater concentrations of butyrate in the distal colon. It was concluded that eating black beans 
and navy beans significantly lowered colon cancer incidence and multiplicity. [48] 
Subramanian Venkateswaran et al., (2002) studied the antioxidant effect of an aqueous 
extract of Phaseolus vulgaris pods, an indigenous plant used in Ayurvedic medicine in India, 
was studied in rats with streptozotocin-induced diabetes. Oral administration of Phaseolus 
vulgaris pod extract (PPEt; 200 mg/kg body weight) for 45 days resulted in a significant 
reduction in thiobarbituric acid reactive substances and hydroperoxides. The extract also 
causes a significant increase in reduced glutathione, superoxide dismutase, catalase, 
glutathione peroxidase and glutathione-S-transferase in the liver and kidneys of rats with 
streptozotocin-induced diabetes. These results clearly show the antioxidant property of PPEt. 
The effect of PPEt at 200 mg/kg body weight was more effective than glibenclamide. [49]  
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SCOPE AND PLAN OF WORK 
Scope: 
Kidney stones are hard deposits of minerals like calcium either in urinary tract 
(urolithiasis) or in kidneys (nephrolithiasis). Along with plenty of fluid intake and urinary 
retention, the management of urolithiasis also includes combined surgical and medical 
approach using percutaneous nephrolithotomy (PCNL), extracorporeal shock wave lithotripsy 
(ESWL) and antibiotics. Surgical treatments are relatively costly, painful and require expert 
hand and availability of appropriate equipment. This has led to a trigger in search of natural 
resources possessing antiurolithiatic activity. [23] In spite of tremendous advances in the field 
of medicine, there is no truly satisfactory drug for the treatment of renal calculi. Most patients 
still have to undergo surgery to rid of this painful disease.  
Many remedies have been employed during ages to treat renal stones. Most of 
remedies were taken from plants and proved to be useful, though the rationale behind their 
use is not well established except for a few plants and some proprietary composite herbal 
drugs and they are reported to be effective with no side effects. Hence the search for 
antilithiatic drugs from natural sources has assumed greater importance. [24] 
The literature search reveals the potential of several plant drugs such as seeds of  
Trachyspermum ammi (L) Sprague ex (umbelliferae), seeds of  Armoracia lopathifolia 
(Brassicaceae), rhizomes of Bergenia ligulata (Saxifragaceae), seeds of Agrimonia eupatoria 
L( fabaceae) in managing Lithiasis in animal models[ 50-52]. 
Phaseolus vulgaris, also known as kidney beans, is a common Indian dish. The seeds 
of Phaseolus vulgaris are gaining increasing attention as a functional or nutraceutical food, 
due to its rich variety of phytochemicals such as proteins, amino acids, complex 
carbohydrates, dietary fibers, oligosaccharides, phenols, saponins, flavonoids, alkaloids, and 
tannins, with potential health benefits. The seeds were claimed to possess diuretic activity 
and were commonly used in water retention treatment in pregnant women. Studies indicate 
that seeds of Phaseolus vulgaris were found to have activities such as enhancement of the 
bifidogenic, antioxidant, antimutagenic, anticarcinogenic, and antihyperglycemic effects. [58]  
Phaseolus vulgaris Linn an easily available plant in India has been explored for the 
possession of analgesic and anti-inflammatory activity, Antioxidant activity, Anti-obesity, 
Antibacterial, Anticancer, Antidiabetic, Antifertility, Hepatoprotective, Hypolipidemic, 
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Trypsin and α-amylase inhibitor, Hyperglycaemic activity, Low nitrate stress, Anti tubular 
activity ,Atypical anti-psychotic, and Anti-fungal activity.[55-66]   
          The present study is aimed at evaluating the antiurolithiatic activity of the ethanolic 
extract and aqueous extracts of the seeds of Phaseolus vulgaris was investigated in Wistar 
rats against Calcium oxalate urolithiasis induced by ethylene glycol (EG) and ammonium 
chloride (AC) in drinking water. 
The recurrence of urolithiasis represents a serious problem, as patients who have 
formed a stone are more likely to form another, and thus stone prevention is highly 
recommended.   Therefore the prophylactic use of the extracts in urolithiasis is also evaluated 
in the study.   
 
OBJECTIVES: 
1. To prepare aqueous and ethanolic extracts of Phaseolus vulgaris seeds and 
characterise its phytochemical nature by preliminary screening, TLC and 
quantification of some phyto constituents. 
2. To evaluate the anti-oxidant action of Phaseolus vulgaris in 3 invitro models. 
3. To investigate the anti urolithiatic activity of Phaseolus vulgaris in wistar albino rats 
by preventive and curative studies. 
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PLAN OF WORK 
  The present study is designed and carried out by the following methods to evaluate 
the anti urolithiatic activity of Phaseolus vulgaris  
1. Collection and Authentication of plant. 
2. Preparation of aqueous and ethanolic extracts of Phaseolus vulgaris 
3. Identification of phytoconstituents of extracts. 
  Preliminary phyto chemical screening. 
  TLC study of extract. 
4. Determination of Phyto constituents of extracts 
 Determination of Total Flavonoid content 
 Determination of Total Phenolic content 
5. In vitro antioxidant studies on the extracts. 
 Determination of Nitric oxide Scavenging Assay. 
 Determination of Reducing Power Assay. 
 Determination of lipid Peroxidation Assay. 
6. Pharmacological study: 
 Evaluation of anti lithiatic activity: 
A. Selection of animals 
 B. Induction of Lithiasis 
C. Experimental design 
D. Assessment of antilithiatic activity. 
        Urine analysis 
        Serum analysis 
E. Histopathological Study of kidney. 
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4. PLANT PROFILE 
 
 
 
     
                 Figure No: 5 Phaseolus vulgaris Linn. seeds 
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SCIENTIFIC CLASSIFICATION: [53] 
Kingdom                 :   Plantae 
Division                   :   Tracheophyta 
Sub division            :   Spermatophytina 
Class                        :   Magnoliopsida 
Order                       :   Fabales  
Family                     :   Fabaceae 
  Genus                     :   Phaseolus 
  Species                   :    vulgaris L.  
SYNONYMS OF PLANT: [54] 
 Phaseolus aborigineus  Burkart 
 Phaseolus communis  Pritz. 
 Phaseolus compressus  DC. 
 Phaseolus esculentus  Salisb. 
 Phaseolus nanus L. 
LOCAL NAMES OF PLANT: [55] 
Burmese                 :   Bo-Sa-Pe 
Tamil                      :   Naarila vithai avarai  
French                    :   Hericots verts 
German                  :   Gartenbohne 
Gujarati                  :   Phanasi 
Hindi                      :   Bakla 
Kannada                 :   Tingalavari 
Marathi                   :   Shravanghevda 
Punjabi                    :   Babri 
Telugu                     :   Bangalu 
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DISTRIBUTION: [56] 
Tropical America. Beans are cultivated in all parts of the world and multitude of 
cultivars and beans type has been developed. The plant is indigenous to America. 
 
DESCRIPTION: [57] 
Bush varieties: Erect bushes 20–60 cm (8–20 in) tall, while pole or running varieties form 
vines 2–3 m (7–10 ft) long. 
Leaves: Alternate, green or purple leaves, which are divided into three oval, smooth edged 
leaflets, each 6–15 cm (2–6 in) long and 3–11 cm (1–4 in) wide.  
Flowers:  The white, pink, or purple flowers are about 1 cm long 
Pods: The pods are 8– 20 cm (3–8 in) long and 1–1.5 cm wide. These may be green, yellow, 
black, or purple in color, each containing 4–6 beans. 
Seeds: The seeds are smooth, plump, kidney-shaped, up to 1.5 cm long, range widely in 
color, and are often mottled in two or more colors. 
Fruit: The fruit are in lightly, blossomed, and shorter then their leaves 
 
PHYTO CHEMICAL CONSTITUENTS: [58] 
Anthocyanins, brassinosteroids, caffeic acid, catechic and coumestrol, daidzen, 
delphinidin, equol, ferulic acid, galactomanans, gallic acid, genistein, hemagglutinins, 
kaempferol, lectins, malvidin, myrecitin glycoside, para-coumaric acid, petunidin, 
phaseolamin, phaseolin, para-hydroxybenzoic acid, phytic acid, phytohaemagglutinin, 
proanthocyanidins, proanthocyanins, quercetin, robinin and vanillic acid. Allantoin, inositol, 
tyrosine, leucine, arginine, amino acid, L-pipecolic acid. 
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MEDICINAL USES: [59-66] 
 Analgesic and anti inflammatory activity 
 Antioxidant activity 
 Anti obesity 
 Antibacterial 
 Anticancer 
 Antidiabetic  
 Antifertility 
 Hepatoprotective 
 Hypolipidemic  
 Litholytic 
 Trypsin and α-amylase inhibitor.   
 Hyperglycaemic activity 
 Low nitrate stress 
 Anti-tubular activity 
 Atypical anti-psychotic 
 Anti-fungal activity 
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5. MATERIALS AND METHODS 
 
1. PLANT COLLECTION AND AUTHENTICATION: 
The seeds of Phaseolus vulgaris Linn were collected from farmers of Ooty, Tamil 
Nadu, India. They were authenticated by Dr. Stephen Ph.D., Professor, Dept. of Botany, 
American College, Madurai.  
2. PREPARATION OF EXTRACTS  Phaseolus vulgaris Linn:  
AQUEOUS EXTRACT 
Coarse powder of Phaseolus vulgaris Linn seeds (300 grams) were extracted by cold 
maceration using water for 15 days. The extract was concentrated by surface evaporation 
followed by vacuum drying. Dry powder was weighed and sored in air-tight containers for 
further Phytochemical and pharmacological studies.  
 
ETHANOLIC EXTRACT 
Coarse powder of Phaseolus vulgaris Linn seeds was extracted with 250 ml of 
ethanol by hot percolation method using soxhlet apparatus. The extraction was carried out for 
72 hours. After extraction, the solvent was distilled out to obtain a concentrated extract. Then 
the concentrated extract was vacuum dried and the dry extract was stored in an air tight 
container for further Phytochemical and pharmacological studies. 
 
3. IDENTIFICATION OF PHYTOCONSTITUENTS OF EXTRACTS :         
  I. Preliminary phytochemical screening: [68, 69, 70] 
Preliminary phytoconstituents present in the ethanol extract and aqueous extract of 
Phaseolus vulgaris were identified based on the following chemical tests. 
 1. Tests For Carbohydrates: 
a. Molisch’s test: 
To 2-3 ml of aqueous extract, added few drops of alpha naphthol solution in alcohol, 
shaken and then added concentrated sulphuric acid from sides of test tube. A brown purple 
ring formed at the junction of the two liquids indicates the presence of sugars. 
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b. Fehling’s test: 
Mixed 1 ml Fehling’s solution A and 1ml of Fehling’s solution B and boiled for 1 
minute, added equal volume of test solution and heated on boiling water bath for 5-10 mins. 
Formation of brick red precipitate confirms the presence of sugars. 
c. Benedict’s test: 
Mixed equal volume of Benedict’s reagent and test solution in a test tube, heated in 
boiling water bath for 5 mins. Formation of brick red precipitate confirms the presence of  
sugars.  
d. Barfoed’s test:               
Mixed equal volume of Barfoed’s reagent and test solution. Heated for 1-2 mins in 
boiling water bath and cooled. An orange red precipitate confirms the presence of sugars. 
 2. Tests for glycosides: 
Heated on a water bath and the hydrolysate was  subjected to Legal, Keller Killiani, 
Borntrager’s and modified  Borntrager’s test to detect the presence of glycosides. 
a. Legal test: 
 To the hydrolysate, 1 ml of pyridine and few drops of sodium nitroprusside solution 
were added and then it was made alkaline with sodium hydroxide solution. A blood red 
colour indicates the presence of glycosides. 
b. Borntrager’s test: 
             The hydrolysate was treated with chloroform and the chloroform layer was 
separated. To this, equal quantity of dilute ammonia solution was added. A light pink colour 
at the interface between two liquids indicates the presence of glycosides. 
3. Test for alkaloids: 
a. Mayer’s test: 
              Methanolic extract was treated with drops of hydrochloric acid and filtered. The 
filtrate was treated with Mayer’s reagent.  Yellowish buff colour indicates the presence of 
alkaloids. 
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b. Dragendroffs test: 
        Methanolic extract was treated with few drops of Dragendroff’s reagent. Orange red 
precipitate indicates the presence of alkaloids. 
c.Wagner’s test: 
           Methanolic extract was treated with drops of hydrochloric acid and filtered’ The 
filtrate was treated with Wagner’s reagent. Reddish brown colour  precipitate indicates the 
presence of alkaloids. 
4. Tests for flavonoids: 
a. A small quantity of solvent free methanolic extract was dissolved in alcohol separately and 
it was extracted with 10% sulphuric acid and cooled. Then it was extracted with diethyl ether 
and divided in to three portions in two separate test tubes for each extract. 1ml of sodium 
carbonate, 1ml of sodium hydroxide and 1ml of diluted ammonia solution were added to the 
first and second test tubes respectively.  In each test tube development of yellow colour 
demonstrated the presence of flavonoids.  
b. Ferric chloride test: 
          To a small quantity of the alcohol solution of extract few drops of neutral ferric 
chloride solution were added. Formation of blackish red colour demonstrated the presence of 
flavonoids. 
c. Shinoda’s test: 
         To the alcoholic solution of extract a small piece of magnesium ribbon and few drops 
of concentrated hydrochloric acid were added  and heated, a magenta colour indicates the 
presence of flavonoids in methanol extract . 
5. Tests for proteins: 
a. Biuret test: 
The extract was treated with equal volume of 40% of sodium hydroxide and 2 drops 
of 1% copper sulphate solution . Pink or purple colour indicates the presence of proteins.  
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b. Millon’s test: 
             To the extract, few drops of Millon’s reagent was added and heated. Appearance of 
red colour indicates the presence of proteins and  free amino acids . 
 
C. Ninhydrin test: 
           A small quantity of extract solution was boiled 0.2% solution of Ninhydrin. Blue 
colour indicates the presence of free amino acids. 
6.Tests for tannins: 
Small quantity of the extract was dissolved in distilled water,  filtered and tested for 
the presence of phenolic compounds and tannins  using the following reagents:  
 
A. With dilute ferric chloride solution (5%) – development of greenish black coloration 
indicates the presence of tannins. 
B. With 10% lead acetate solution – development of yellow colour precipitate indicates the 
presence of tannis. 
C. With 10% aqueous potassium dichromate solution – development of yellowish brown 
precipitate indicates the presence of tannis. 
 
7. Test for saponins: 
 Foam test: 
To the extract, 20ml of distilled water and agitated in a graduated cylinder for15 
minutes. The formation of about 1cm layer of foam indicates the presence of saponins. 
8. Tests for steroids and triterpenoids: 
A. Libermann - Burchard reaction: 
          Small quantities of solvent free methanol extract were separately dissolved in 1ml 
chloroform and 1ml of acetic anhydride was then added followed by 2ml of concentrated 
sulphuric acid. A reddish violet ring at the junction of the two layers indicates the presence of 
triterpenoids and steroids. 
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b.Salkowski’s test: 
          Concentrated sulphuric acid was added to a chloroform solution of the extract (10mg 
of extract in 1ml of chloroform), a reddish blue colour in the chloroform layer and green 
fluorescence in acid layer, suggests the presence of steroids. 
9. Test for sterols : 
When the extracts were treated with 5% potassium hydroxide solution, appearance of 
pink colour indicates the presence of sterols. 
10. Test for phenols: 
When the extracts were treated with neutral ferric chloride solution, appearance of 
violet colour indicates the presense of phenols. When the extracts were treated with 10% 
sodium chloride solution, the appearance of cream colour indicates the presence of phenol.  
 
11. Test for Terpenoids: 
         About 0.5 g of plant extract in separate test tube was taken with 2 ml of chloroform; 5 
ml of concentrated sulphuric acid was carefully added to form a layer and observed for 
presence of reddish brown colour interface to show positive results for the presence of 
terpenoids. 
 
 ⅠⅠ. TLC Study on the extracts: [74] 
The ethanolic extract of phaseolus vulgaris (EEPV) was dissolved in ethanol. Then 
the solution was applied on Merck Aluminium plate pre coated with silica gel 60 F254 of 0.2-
0.5 mm thickness. The plate was developed in Chloroform: Methanol: Distilled water: 
Toluene (8:1:0.5:0.5) solvent system. After visualization Rf values were calculated.  
The aqueous extract of phaseolus vulgaris (AEPV) was dissolved in water. Then the 
solution was applied on Merck Aluminium plate pre coated with silica gel 60 F254 of 0.2-0.5 
mm thickness. The plate was developed in Chloroform: Methanol: Distilled water: Toluene 
(8:1:0.5:0.5) solvent system. After visualization Rf values were calculated.  
                                         Distance travelled by solute       
                   Rf value =   ------------------------------------ 
                                        Distance travelled by solvent   
                                                                                                                          Materials and Methods 
Dept of Pharmacology, Ultra College of Pharmacy.         Page 50  
                                
4. DETERMINATION OF PHYTOCONSTITUENTS OF EXTRACTS 
   Ⅰ. Determination of total flavonoid content: [75] 
Preparation of standard: 
      Standard solution was prepared by adding 10 mg of accurately weighed Quercetin in 
10 ml of distilled water. 
Preparation of sample: 
10 mg of the accurately weighed AEPV and EEPV extracts were separately dissolved 
in 10 ml water and used for the estimation. 
Procedure: 
     The total flavoniod content of the AEPV and EEPV was determined by using 
aluminium chloride colorimetric method.  To an aliquot of 1 ml of extract (1mg /ml)  or 
standard solutions of Quercetin (10,20,40,60,80.100, µg/ml)  methanol was added separately 
to make up the solution upto 2ml. The resulting mixture was treated with 0.1ml of potassium 
acetate and 2.8 ml of distilled water.  Shaken well and incubated at room temperature for 30 
minutes.  The absorbance was measured at 415nm against blank, where a solution of 2ml 
ethanol 0.1ml potassium aetate, 2.8ml distilled water and 0.1ml of aluminium chloride serve 
as blank solution. The total flavanoid content was determined from the standard quercetin 
calibration curve.  And it was expressed as milligrams of Quercetin equivalents (QE) per 
gram of extract  
 Ⅱ. Determination of total phenolic content: [75] 
 Preparation of standard: 
     Standard solution was preapared by adding 10mg of accurately weighed Gallic acid in 
10 ml of distilled water 
Prepartion of sample: 
   10mg of the accurately weighed AEPV and EEPV extracts were separately dissolved 
in 10ml ethanol and used for the estimation. 
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Procedure: 
     The total phenolic content of the AEPV and EEPV was determined by Folin 
Ciocalteau assay method.  To an aliquot 100µg of AEPV or standard solution of Gallic acid 
(10, 20, 40, 60, 80,100µg/ml) added 0.5ml of Folin Ciocalteau reagent and made into 2ml 
with distilled water and the mixture is incubated for 5min at room temperature .  0.1ml of 
20% Sodium Carbonate and 0.9ml of distilled water were added to make the final solution to 
3ml.  It was incubated for 30 ins in dark to complete the reaction .After that absorbance of the 
mixture was measured at 725nm against blank. Distilled water was used as reagent blank.  
The tests were performed in triplicate to get mean the values. The total phenolic content was 
found out from the calibration curve of Gallic acid.  And it was expressed as milligrams of 
Gallic acid equivalents (GAE) Per gram of extract. 
5. IN VITRO ANTIOXIDANT STUDIES ON THE EXTRACTS: 
1. Determination of Nitric Oxide Scavenging Assay:  [71] 
The activity was measured according to the modified method of Sreejayan and Rao, 
To 4ml of the extract having different concentrations (100-500 µg/ml), 1 ml of sodium 
nitroprusside (SNP) solution (5mM) was added and incubated for 2hr at 27˚C.An aliquot 
(2ml) of the incubation solution was removed and diluted with 1.2ml of Griess reagent (1% 
Sulfanilamide in 5% H3PO4 and 0.1% naphthylethylene diamine dihydrochloride). The 
absorbance of the chromophore was read at 550nm and compared with standard, Ascarbic 
Acid.  
Nitric oxide scavenging activity (%) = (Abscontrol Abs sample) x100(Abs control)

     
 
Where, Abs (control): Absorbance of the control and Abs (sample): Absorbance of 
the extracts/standard. 
 
  ⅠⅠ. Determination of Reducing Power Assay: [72] 
           Various concentrations of the plant extracts in corresponding solvents were mixed 
with phosphate buffer (2.5ml) and potassium ferricyanide (2.5ml) . This mixture was kept at 
50˚C in water bath for 20 minutes. After cooling, 2.5ml of 10% trichloro acetic acid was 
added and centrifuged at 3000 rpm for 10mins whenever necessary. The upper layer solution 
(2.5ml) was mixed with distilled water (2.5ml)  and a freshly prepared ferric chloride solution 
(0.5ml) . The absorbance was measured at700nm. Control was prepared in similar manner 
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excluding samples. Ascorbic acid at various concentrations was used as standard. Increased 
absorbance of the reaction mixture indicates increase in reducing power.  
 
ⅠⅠⅠ. Determination of Lipid Peroxidation Assay: [73] 
               Egg homogenate (10% in 1.15% potassium chloride, v/v ) 0.1 ml of extract/standard 
( 100-500µg ) were mixed in a test tube and the volume was made up to 2ml, by adding 
distilled water . Finally, 0.5 ml FeSO4 (0.07M) was added to the above mixture and incubated 
for 30 minutes, to induce lipid peroxidation . Thereafter, 0.5ml of 20% acetic acid (pH 3.5) 
and 0.5ml of 0.8% TBA (w/v) (prepared in 1.1% sodium dodecyl sulphate) and 0.5ml 20% 
TCA were added, vortexed, and then heated in a boiling water bath for 60mins. After cooling, 
5.0ml of 1-butanol was added to each tube and centrifuged at 3000 rpm for 10mins. The 
absorbance of the organic upper layer was measured at 532nm. For the blank 1.0ml of 
distilled water was used in place of the extact.  
 
                 AI= (1- T/C) x 100 
 
               Where T =   absorbance of Test, C =  absorbance of fully oxidized control. 
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6. PHARMACOLOGICAL SCREENING FOR ANTILITHIATIC ACTIVITY: 
   Experimental Animals: 
            Wistar rats of either sex, weighing 150-200g were maintened in Animal house. The 
selected animals were grouped and housed in polypropylene cages in standard environmental 
conditions at 23 ± 20 with 12:12 Hr dark and light cycle. The animal had free acess to food 
and water ad libitum. All animals were housed standard hygienic laboratory condition one 
week prior to testing. 
               The experiments on animals were conducted in accordance with the Experimental 
protocols duly approved by Institutional Animal Ethical Committee.  
Proposal No: (IAEC/ T.VINCIYA/ TNMGRMU/ M.PHARM/ KMCP/ 06/ 2017-2018) 
Experimental Design: [9] 
          Rats were divided into nine groups of three animals each (n = 3). CaOx stones were 
induced in rats by administering 0.75% v/v of EG and 1 % w/v of AC in drinking water for 
15 days. Cystone (750 mg/kg) was used as a standard drug, and extract of phaseolus vulgaris 
(EPV) was administered at doses of 200 and 400 mg/kg. Both preventive and curative effects 
of EPV were evaluated. All groups were maintain on commercial pellet diet for 28 day. 
              The treatment schedule was planned as follows: 
 Group I: Normal (untreated) 
 Group II: Preventive control (EG + AC + vehicle from day 1 to 15)  
Group III: Preventive standard (EG + AC + cystone 750 mg/ kg, orally from day 1 to 15) 
Group IV: Preventive low dose (EG + AC + EPV 200 mg/kg, orally from day 1 to 15) 
 Group V: Preventive high dose (EG +AC + EPV 400 mg/kg, orally from day 1 to 15)  
Group VI: Curative control (EG + AC from day 1 to 15, vehicle from day 16 to 30) 
 Group VII: Curative standard (EG + AC from day 1 to 15; cystone 750 mg/kg, orally from 
day 16 to 30) 
Group VIII: Curative low dose (EG + AC from day 1 to 15, EPV 200 mg/kg, orally from day 
16 to 30)  
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Group IX: Curative high dose (EG + AC from day 1 to 15, EPV 400 mg/kg, orally from day 
16 to 30) 
ASSESSMENT OF ANTIUROLITHIATIC ACTIVITY: [25] 
Urine collection and analysis : 
   At the end of the 14th and 28th day, the animals were kept separately in metabolic 
cages for 24 hours for urine collection. Animals had free access to drinking water during the 
urine collection period.   
The collected urine samples were measured for the following parameters:  
Urine volume, Creatinine, Calcium, Magnesium, Oxalate, Phosphate. 
Urine volume:  measured using the measuring cylinder and reported per ml. 
Calcium  and magnesium: determined by Colourimetric method. 
Oxalate: determined by  hodgkinson and Williams method. 
Phosphate: using fiske and subbarow method. 
Serum Analysis: 
     Blood samples were collected from the retro-orbital venous plexus and serum was 
separated by centrifuging at 1500 rpm for 15 min and used for the estimation of uric acid, 
creatinine, and Blood urea nitrogen (BUN) using ERBA diagnostic kits according to the 
manufacturer’s instructions. Fully automated autoanalyzer (Erba EM-200, Transasia Bio-
medicals Ltd, Mumbai) was used for the estimations. 
E. Histopathological examination: [9] 
           Immediately after blood sampling, animals were sacrificed by cervical dislocation 
under ether anesthesia. No animal died prior to this experimental end point. The two kidneys 
from each rat were immediately dissected out and rinsed with Phosphate buffered saline 
(PBS)  to remove excess blood. kidneys from all groups were fixed in 10% neutral buffered 
formalin for 72h at least, washed, dehydrated, and embedded in paraffin. Sections of 5μm 
thickness were stained with Hematoxylin and Eosin (H&E).  
 
                                                                                                                          Materials and Methods 
Dept of Pharmacology, Ultra College of Pharmacy.         Page 55  
                                
Statistical Analysis:  
     Datas’s of all the parameters were analysed using the Graph pad 7.0 software. 
Analysis of Variance (ANOVA); one way ANOVA followed by Dunnetts t test was 
performed. The values were expressed as Mean ± SEM. P value <0.05, p<0.01 was 
considered as significant.  
 Results and Analysis 
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6. RESULTS AND ANALYSIS 
 
1. EXTRACTIVE YIELD OF Phaseolus vulgaris linn: 
 
 The percentage yield of ethanolic and aqueous extract of seeds of Phaseolus vulgaris 
linn was found to be 
        Ethanolic extract: 8.24 % w/w. 
       Aqueous extract: 6.32 % w/w.  
 
2. IDENTIFICATION OF PHYTOCONSTITUENTS OF EXTRACTS: 
1. Preliminary Phytochemical screening of Phaseolus vulgaris: 
     Preliminary Phytochemical screening of Phaseolus vulgaris, revealed the 
presence of following phytoconstituents. 
 
Table No: 1. Results of preliminary Phytochemical screening of Phaseolus vulgaris 
 
S No 
 
Constituents 
Observation 
Ethanol Aqueous 
1 Alkaloids + + 
2 Carbohydrates + + 
3 Proteins & amino acids + + 
4 Steroids + + 
5 Phenols + + 
6 Tannins + + 
7 Flavonoids + + 
8 Glycosides + + 
9 Saponins _ + 
10          Terpenoids + + 
 
(-) indicates the absence of compound 
(+) indicates the presence of compound 
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ⅠⅠ. Thin Layer Chromatography of Phaseolus vulgaris:  
 TLC study was carried out for the separation and identification of phytoconstituents in 
Phaseolus vulgaris, after development visualization was done with Iodine. Rf values 
werecalculated. 
 
         Aqueous extract                                       Ethanolic extract  
                            
 Figure No: 6. TLC  Identification of phytoconstituents in AEPV and EEPV 
 
Table No: 2. Results of TLC screening of phaseolus vulgaris 
Aqueous extract Ethanolic extract 
No of Spot Rf  Value No of Spot Rf  Value 
1 0.38 1 0.16 
2 0.83 2 0.41 
  
3 0.55 
  
4 0.88 
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3. DETERMINATION OF PHYTOCONSTITUENTS OF EXTRACTS: 
1. Determination of Total Flavonoid content: 
Table: 3 Determination of Total Flavonoid content 
Sample 
 
Concentration µg/ml OD value 
Standard 
(Quercetin) 
1mg/ml 
10 0.03 
20 0.09 
40 0.26 
60 0.5 
80 0.78 
100 1.05 
AEPV 
1 mg/ml 
 
100 0.04 
100 0.05 
100 0.04 
EEPV 
1 mg/ml 
100 0.06 
100 0.04 
100 0.04 
 
 
Figure No: 8 Determination of Total Flavonoid content 
Total Flavonoid Content of AEPV was found to be 8.81 mg Quercetin Equivalents / g plant 
Extract. 
Total Flavonoid Content of EEPV was found to be 9.18 mg Quercetin Equivalents / g plant 
Extract. 
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Ⅱ. Determination of Total Phenolic content: 
Table No: 4 Determination of Total Phenolic content: 
               Sample 
 
Concentration µg/ml OD value 
Standard 
(Gallic Acid) 
1mg/ml 
10 0.09 
20 0.12 
40 0.21 
60 0.34 
80 0.40 
100 0.50 
AEPV 
1 mg/ml 
 
100 0.13 
100 0.13 
100 0.11 
EEPV 
1 mg/ml 
100 0.15 
100 0.19 
100 0.13 
 
 
 
      Figure No: 9 Determination of Total Phenolic content 
Total Phenolic Content of AEPV was found to be 30.10 mg Gallic acid Equivalents / g plant 
Extract. 
Total Phenolic Content of EEPV was found to be 42.22 mg Gallic acid Equivalents / g plant 
Extract. 
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4. IN VITRO ANTI OXIDANT STUDIES ON THE EXTRACT: 
 
1. Determination of Nitric Oxide Scavenging Assay:                                                           
EEPV: Ethanolic extract ofPhaseolus vulgaris 
           AEPV: Aqueous extract of Phaseolus vulgaris 
Table 5. Determination of Nitric Oxide Scavenging Assay 
S. 
no 
 
 
Concentration 
µg/ml 
% of Inhibition IC 50 Value (µg/ml) 
Ascorbic 
Acid 
EEPV AEPV Ascorbic 
Acid 
EEPV AEPV 
1 
 
 
200 86.38±1.32 23.25±1.77 59.04±2.34 98.26 651 195 
 
2 
400 90.33±1.56 40.69±1.02 63.33±1.09 
3 
 
600 91.41±1.52 47.28±1.55 84.76±0.62 
4 
 
800 92.93±1.76 64.72±1.02 87.37±0.23 
5 
 
1000 93.94±1.49 72.85±1.404 91.41±0.41 
Values are mean ± SEM of 3 replicates 
 
 
Figure No: 9 Determination of Nitric Oxide Scavenging Assay 
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ⅠⅠ. DETERMINATION OF REDUCING POWER ASSAY: 
 
Table No: 6. Determination of Reducing Power Assay: 
S. No Concentration 
µg/ml 
OD value 
 
Ascorbic 
Acid 
EEPV AEPV 
1 
 
200 1.23 ± 0.06 0.18 ± 0.008 0.47 ± 0.01 
2 
 
400 
 
1.61 ± 0.04 0.21 ±0.01 0.60 ± 0.02 
3 
 
600 1.68  ±0.04 0.41 ± 0.01 0.94 ± 0.03 
4 
 
800 1.77 ± 0.07 0.64 ±0.02 1.19 ±0.04 
5 
 
1000 1.80  ± 0.08 1.04 ±0.04 1.41 ±  0.01 
 
Values are mean ± SEM of 3 replicates 
 
 
Figure No: 10 Determination of Reducing Power Assay 
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III. DETERMINATION OF LIPID PEROXIDATION ASSAY: 
 
Table No: 7. Determination of Lipid Peroxidation Assay: 
 
 
S. 
no 
 
 
Concentration 
µg/ml 
% of Inhibition IC 50 Value (µg/ml) 
Ascorbic 
Acid 
EEPV AEPV Ascorbic 
Acid 
EEPV AEPV 
1 
 
200 70.5±1.32 25.99±1.77 21.71±2.9  
 
 
 
171.66 
 
 
 
 
700.66 
 
 
 
 
732.22 
2 
 
400 77.31±1.62 38.09±1.17 31.81±0.87 
3 
 
600 82.35±1.21 46.02±0.81 43.93±1.57 
4 
 
800 86.55±1.45 55.55±1.58 54.28±2.20 
5 
 
1000 90.76±1.68 60.29±1.20 60.09±1.10 
 
Values are mean ± SEM of 3 replicates 
 
 
Figure No: 11. Determination of Lipid Peroxidation Assay 
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5. PHARMACOLOGICAL STUDIES 
 
A. PREVENTIVE STUDY 
 
Effect of AEPV on Urine Volume and Urine biochemical parameters on 14th  day 
 
Table No: 8. Effect of AEPV on Urine Volume and Urine biochemical parameters on 
14th  day 
 
 
Group 
URINE ANALYSIS 
Urinary        
volume  
(ml/24 h) 
Calcium 
(mg/dl) 
Oxalate 
(mg/dl) 
phosphate 
(mg/dl) 
Magnesium 
(mg/dl) 
Normal 
 
 
9.71±0.63    4.48±0.166 1.15±0.434 5.61±0.25 1.44±0.23 
Lithiatic control 
(un treated) 
 
4.10±0.88 7.465±0.357 3.06±0.042 8.58±0.24 0.65±0.09 
Positive control 
(cystone 
treated) 
9.16±1.04* 6.029±0.09* 1.38±0.35** 6.64±0.26** 1.26±0.03** 
AEPV Low 
dose(200mg/kg) 
 
5.91±0.40ns 5.82±0.27* 1.37±0.33** 6.42±0.06** 1.21±0.06** 
AEPV  high 
dose 
(400mg/kg) 
 
7.33±0.76* 
 
 
6.17±0.08* 1.41±0.34** 6.72±0.18** 1.38±0.08** 
 
Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly different 
when compared with lithiatic control mean values at P<0.05, P<0.01, P<0.001and non-
significant respectively 
Effect of AEPV on Urine Volume and Urine biochemical parameters on 14th  day was 
1. Urinary volume in Lithiatic group is decreased, positive control group is increased. Urinary 
volume in AEPV in high dose is increased compared to the low dose. 
2. Calcium, Oxalate, Phosphate level in Lithiatic group is increased, positive control and the 
extracts of AEPV in low dose and high dose may be decreased. 
3. Magnesium level in Lithiatic group is decreased, positive control and the extracts of AEPV 
in low dose and high dose may be increased.  
 Results and Analysis 
Dept of Pharmacology, Ultra College of Pharmacy.           Page 64 
                                 
 
 
         Figure No: 12. The 24 hr calcium concentration in rats urine on day 14 
 
 
       Figure No: 13. The 24 hr oxalate concentration in rats urine on day 14 
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Figure No: 14. The 24 hr phosphate concentration in rats urine on day 14 
 
Figure No: 15. The 24 hr magnesium concentration in rats urine on day 14 
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Effect of  AEPV on serum biochemical  parameters on 14th  day 
 Table No: 9. Effect of  AEPV on serum biochemical  parameters on 14th  day 
 
       GROUP 
SERUM ANALYSIS (mg/dl) 
Creatinine Urea BUN  
(Blood urea nitrogen) 
Normal 
 
1.107±0.23 1.957±0.26 37.6±0.23 
Lithiatic control 
(un treated) 
2.06±0.16 5.46±0.63 46.17±2.49 
Positive control 
(cystone treated) 
0.723±0.014** 1.65±0.02** 31.19±4.04* 
AEPV Low 
dose(200mg/kg) 
0.93±0.058** 1.65±0.075** 34.37±3.25* 
AEPV  high  
dose(400mg/kg) 
0.906±0.017** 1.83±0.06** 35.4±2.8* 
 
 Values are expressed as Mean ± SEM. *, **, ***,  ns  - Mean values are significantly 
different when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and 
non-significant respectively 
 
 
 
 
 
 
 
 
 Results and Analysis 
Dept of Pharmacology, Ultra College of Pharmacy.           Page 67 
                                 
 
 
Figure No: 16. The creatinine excretion in rats blood on day 14 
 
 
Figure No: 17. The urea excretion in rats blood on day 14 
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Figure No: 18. The BUN excretion in rats blood on day 14 
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Effect of  EEPV on Urine Volume and Urine biochemical parameters on 14th  day 
Table No: 10. Effect of  EEPV on Urine Volume and Urine biochemical parameters on 
14th  day 
 
 
Group 
URINE ANALYSIS 
Urinary        
volume  
(ml/24 h) 
Calcium 
(mg/dl) 
Oxalate 
(mg/dl) 
phosphate 
(mg/dl) 
Magnesium 
(mg/dl) 
Normal 
 
7.89±0.12 5.7±0.24 0.34±0.013 5.83±0.39 0.96±0.59 
Lithiatic control 
(un treated) 
 
4.82±0.17 7.39±0.53 3.57±0.01 8.93±0.28 0.55±0.01 
Positive control 
(cystone 
treated) 
6.8±0.04*** 4.28±0.37** 1.32±0.02* 6.68±0.11* 1.28±0.04* 
EEPV Low 
dose(200mg/kg) 
 
7.13±0.11*** 5.04±0.23* 1.55±0.05* 7.03±0.07* 1.19±0.06* 
EEPV high 
dose 
(400mg/kg) 
 
 
7.11±0.20*** 
 
 
4.80±0.22* 1.41±0.01* 6.86±0.03* 1.52±0.04* 
 
Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly different 
when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and non-
significant respectively 
     Effect of EEPV on Urine Volume and Urine biochemical parameters on 14th  day was 
1. Urinary volume in Lithiatic group is decreased, positive control group is increased. Urinary 
volume in EEPV in high dose is almost equal to the low dose. 
2.   Calcium,Oxalate, Phospahte level in Lithiatic group is increased, positive control and the 
extracts of  EEPV in low dose and high dose may be decreased.  
3. Magnesium level in Lithiatic group is decresed., positive control and the extracts of  EEPV 
in low dose and high may be increased.  
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Figure No: 19.  The calcium excretion in rats urine on day 14 
 
 
Figure No: 20. The phosphate excretion in rats urine on day 14 
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Figure No: 21. The magnesium excretion in rats urine on day 14 
 
 
 
Figure No: 22. The oxalate excretion in rats urine on day 14 
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Effect of  EEPV on serum biochemical  parameters on 14th  day 
 
               Table No: 11. Effect of  EEPV on serum biochemical  parameters on 14th  day 
 
 
Group 
Serum Analysis (mg/dl) 
Creatinine Uric acid BUN 
(Blood urea nitrogen) 
Normal 
 
0.75±0.01 1.49±0.07 37.62±0.15 
Lithiatic control 
(un treated) 
 
1.73±0.17 4.29±0.14 48.43±0.54 
Positive control 
(cystone treated) 
0.80±0.01* 1.62±0.03* 38.15±1.02* 
EEPV Low 
dose(200mg/kg) 
 
0.88±0.02* 1.92±0.02* 40.43±0.66* 
EEPV high dose 
(400mg/kg) 
 
0.82±0.02* 1.79±0.03* 39.48±0.49* 
 
 Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly 
different when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and 
non-significant respectively. 
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Figure No: 23.  The creatinine excretion in rats blood on day 14 
 
 
 
Figure No: 24. The Uric acid excretion in rats blood on day 14 
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                   Figure No: 25. The BUN excretion in rats blood on day 14 
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Effect of AEPV on Urine Volume and Urine biochemical parameters on 28th  day 
 
Table No: 12. Effect of AEPV on Urine Volume and Urine biochemical parameters on 
28th  day 
 
 
Group 
URINE ANALYSIS 
Urinary        
volume  
(ml/24 h) 
Calcium 
(mg/dl) 
Oxalate 
(mg/dl) 
phosphate 
(mg/dl) 
Magnesium 
(mg/dl) 
Normal 
 
 
5.95±0.13    4.14±0.3796 0.34±0.02 5.85±0.42 0.94±0.01 
Lithiatic control 
(un treated) 
 
3.61±0.14 7.26±0.515 2.47±0.11 8.57±0.419 0.69±0.012 
Positive control 
(cystone treated) 
5.08±0.1*** 7.24±0.53 2.53±0.1 8.56±0.52 0.71±0.01 
AEPV Low 
dose(200mg/kg) 
 
4.16±0.17*** 7.08±0.38 2.4±0.09 8.51±0.57 0.68±0.01 
AEPV  high dose 
(400mg/kg) 
 
4.91±0.13 
*** 
 
5.07±0.43* 0.8±0.04 * 6.29±0.61* 1.09±0.01* 
 
 Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly 
different when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and 
non-significant respectively 
 Effect of AEPV on Urine Volume and Urine biochemical parameters on 28th  day was 
1. Urinary volume in Lithiatic group is decreased, positive control group is increased. Urinary 
volume in AEPV in high dose is almost equal to the low dose. 
2. Calcium, Oxalate, Phosphate level in Lithiatic group is increased, positive control and the 
extracts of  AEPV in low dose and high dose may be decreased.  
3. Magnesium level in Lithiatic group is decreased, positive control and the extracts of  
AEPV in low dose and high may be increased.  
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               Figure No: 26. The calcium excretion in rats urine on day 28 
 
                    Figure No: 27. The oxalate excretion in rats urine on day 28 
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                  Figure No: 28.The phosphate excretion in rats urine on day 28 
 
 
 Figure No: 29. The Magnesium excretion in rats urine on day 28 
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               Effect of  AEPV on serum biochemical  parameters on 28th  day 
 
Table No: 13. Effect of  AEPV on serum biochemical  parameters on 28th  day 
 
GROUP 
SERUM ANALYSIS (mg/dl) 
Creatinine Urea BUN (Blood urea nitrogen) 
Normal 
 
 
0.54±0.02 2.49±0.19 40.13±0.71 
 
Lithiatic control 
(un treated) 
0.99±0.06 4.11±0.25 61.60±0.66 
Positive control 
(cystone treated) 
 
0.39±0.002* 1.80±0.13* 37.41±0.78* 
AEPV Low 
dose(200mg/kg) 
 
0.75±0.05** 2.08±0.026* 42.70±0.94* 
AEPV  high  
dose(400mg/kg) 
 
0.73±0.08** 1.04±0.16* 39.10±0.98* 
 
 Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly 
different when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and 
non-significant respectively 
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Figure No: 30. The creatinine excretion in rats blood on day 28 
 
 
Figure No: 31. The urea excretion in rats blood on day 28 
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Figure No: 32. The BUN excretion in rats blood on day 28 
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Effect of  EEPV on Urine Volume and Urine biochemical parameters on 28th  day 
Table No: 14 Effect of  EEPV on Urine Volume and Urine biochemical parameters on 
28th  day 
 
Group 
URINE ANALYSIS 
Urinary        
volume  
(ml/24 h) 
Calcium 
(mg/dl) 
Oxalate 
(mg/dl) 
phosphate 
(mg/dl) 
Magnesium 
(mg/dl) 
Normal 
 
 
 
7.89±0.12  
4.40±0.59 0.34±0.013 5.83±0.39 0.96±0.59 
Lithiatic control 
(un treated) 
 
4.82±0.17 7.98±0.64 3.07±0.02 8.85±0.61 0.51±0.64 
Positive control 
(cystone 
treated) 
6.8±0.04 6.55±0.32** 1.58±0.04** 6.9±0.59** 1.31±0.32* 
EEPV Low 
dose(200mg/kg) 
 
7.23±0.11 6.15±0.51** 1.78±0.03** 7.83±0.56** 1.29±0.51* 
EEPV high 
dose 
(400mg/kg) 
 
7.21±0.20 
 
 
6.13±0.46** 1.68±0.03* 7.31±0.217** 1.54±0.46* 
 
Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly different 
when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and non-
significant respectively 
     Effect of EEPV on Urine Volume and Urine biochemical parameters on 28th  day was 
1. Urinary volume in Lithiatic group is decreased, positive control group is increased. Urinary 
volume in EEPV in high dose is almost equal to the low dose. 
2. Calcium, Oxalate, Phosphate level in Lithiatic group is increased, positive control and the 
extracts of  EEPV in low dose and high dose may be decreased.  
3. Magnesium level in Lithiatic group is decreased, positive control and the extracts of  
EEPV in low dose and high may be increased.  
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   Figure No: 33. The calcium excretion in rats urine on day 28 
       
Figure No: 34. The Oxalate excretion in rats urine on day 28 
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                   Figure No: 35. The Phosphate excretion in rats urine on day 28 
 
 
  Figure No: 36. The Magnesium excretion in rats urine on day 28 
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Effect of  EEPV on serum biochemical  parameters on 28th  day 
 
           Table No: 15. Effect of  EEPV on serum biochemical  parameters on 28th  day 
 
 
Group 
 
                         Serum Analysis (mg/dl) 
Creatinine Uric acid BUN 
(Blood urea nitrogen) 
Normal 
 
1.54±0.15 1.18±0.08 37.62±0.15 
Lithiatic control 
(un treated) 
 
2.31±0.05 2.56±0.03 41.20±1.45 
Positive control 
(cystone treated) 
1.82±0.05* 1.49±0.05* 26.70±1.48* 
EEPV Low 
dose(200mg/kg) 
 
1.85±0.04* 1.65±0.08* 35.21±1.22* 
EEPV high dose 
(400mg/kg) 
 
2.05±0.07* 2.10±0.16* 32.20±1.41* 
 
 Values are expressed as Mean ± SEM. *, **, ***, ns  - Mean values are significantly 
different when compared with lithiatic control mean values at P <0.05, P<0.01, P<0.001 and 
non-significant respectively 
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Figure No: 37. The Creatinine excretion in rats blood on day 28 
 
 
Figure No: 38. The uric acid excretion in rats blood on day 28 
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Figure No: 39.  The BUN excretion in rats blood on day 28 
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6. HISTOPATHOLOGYSTUDIES: 
                 Histopathological findings of kidney under a light microscope (×40) 
PREVENTIVE STUDY 
 
                 
 
A. Normal                                                           B. Lithiatic control 
 
                                                             
 
C. Low dose (AEPV 200 mg/kg)                                      D. High dose (AEPV 400 mg/kg) 
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         E. Low dose (EEPV 200 mg/kg)                             F. High dose (EEPV 400 mg/kg) 
 
               
                  G. Standard (Cystone) 
                   Figure No: 40    Histopathology of kidney (preventive study) 
 
 
 
 Results and Analysis 
Dept of Pharmacology, Ultra College of Pharmacy.           Page 89 
                                 
 
 
A. Normal:  Renal parenchyma with normal tubules, and glomeruli 
B. Lithiatic control: Oxalate renal stone, tubular dilation and renal tubular damage, severe 
damage to the medulla, glomeruli, tubules. 
C.  Low dose (AEPV 200 mg/kg): Glomerular atrophy and tubular dilation. 
D. High dose (AEPV 400 mg/kg): Regenerated to normal glomerular structure. 
E. Low dose (EEPV 200 mg/kg): Renal tubular dilation and glomerular atrophy. 
F. High dose (EEPV 400 mg/kg): Regenerated to normal glomerular structure 
G. Standard (Cystone): mild vacuolar degeneration of renal tubular epithelial cells.  
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 CURATIVE STUDY: 
                        
      A. Low dose (AEPV 200 mg/kg)                            B. High dose (AEPV 400 mg/kg) 
                                      
C. Low dose (EEPV 200 mg/kg)                                         D. High dose (EEPV 400 mg/kg)  
Figure No: 41. Histopathological study of kidney (Curative study) 
 
A. Low dose (AEPV 200 mg/kg): presence of CaOx crystals in the lumen of dilated renal 
tubules. 
B. High dose (AEPV 400 mg/kg):  mild vacuolar degeneration of renal tubular epithelial cells 
C. Low dose (EEPV 200 mg/kg): Renal tubular dilation and glomerular atrophy. 
D.  High dose (EEPV 400 mg/kg): Regenerated to normal glomerular structure.  
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DISCUSSION 
 
Formation of kidney stones is a complex process and involves a series of biological 
events that are most likely triggered by genetic susceptibility together with dietary factors and 
lifestyle changes. Several in vivo animal models have been developed to investigate the 
mechanisms involved in the formation of urinary stones. However, rat model has been widely 
used for the study of CaOx deposition in the kidneys, a process that mimics the etiology of 
kidney stone formation in humans. Consequently kidney stones formation was induced in 
wistar albino rats by ethylene glycol and ammonium chloride in drinking water model in the 
present study. 
EXTRACTION AND PRELIMINARY PHYTOCHEMICAL STUDIES: 
 The percentage yield of ethanolic and aqueous extract of Phaseolus vulgaris linn was 
found to be 8.24 % w/w and 6.32 % w/w respectively.  
The ethanolic extract (EEPV) was dark brown in colour with a thick viscous 
consistency. The aqueous extract (AEPV) also has a thick viscous consistency and pale 
yellow in colour.     Preliminary Phytochemical screening of EEPV and EEPV revealed the 
presence of  Alkaloids, Carbohydrates, Proteins & amino acids, Steroids, Phenols, Tannins, 
Flavonoids, Terpenoids and Glycosides while the aqueous extract alone possesses saponins. 
(Table No:1) 
These phytochemicals may be responsible for the anticrystallization and antioxidant 
activities. Plant flavonoids are reported to possess antiurolithiatic activity through its 
antioxidant property. Several reports suggest that saponins are having antiurolithiatic activity 
through its diuretic and disaggregating the suspension of mucoproteins. [9] 
The results of TLC separation of the extracts with the mobile phase Chloroform: 
Methanol: Distilled water: Toluene  - 8:1:0.5:0.5 followed by spraying with Iodine showed 2 
spots for aqueous extracts and 4 spots for ethanolic extract (Fig No:6). As the mobile phase 
used is specific for saponins and terpenes, [74] the isolated compounds may be the same. The 
Rf value one of the compounds (0.86) separated with methanolic extract of Phaseolus 
vulgaris seeds using the same mobile phase almost coincides with one of the spots of our 
aqueous extract (0.83)  and one spot in ethanolic extract (0.88). The other spots in the 
ethanolic extracts have Rf values almost similar to that of methanolic extracts of Phaseolus 
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lunatus methanolic extracts. Therefore the spots visualised in the extracts indicate the 
presence of either saponins or terpenes in aqueous extract and only terpenoids in ethanolic 
extract. Therefore the TLC can be the identifying fingerprinting for these extracts in future.  
(Table No:2) 
Determination of Phytoconstituents of extracts: 
Total Flavonoid Content of AEPV was found to be 8.81 mg Quercetin Equivalents / g plant 
Extract. 
Total Flavonoid Content of EEPV was found to be 9.18 mg Quercetin Equivalents / g plant 
Extract (Table No: 3) 
Total Phenolic Content of AEPV was found to be 30.10 mg Gallic acid Equivalents / g plant 
Extract. 
Total Phenolic Content of EEPV was found to be 42.22   mg Gallic acid Equivalents / g plant 
Extract  (Table No: 4) 
 Total Flavonoid Content of EEPV (9.18 mg) was found to be more compared with the AEPV 
(8.81 mg). 
Total Phenolic Content of EEPV (42.22 mg) was found to be more compared with AEPV 
(30.10 mg) 
In vitro antioxidant studies on the extracts:  
The anti oxidant activity of AEPV and EEPV was assessed by three methods namely 
nitric oxide scavenging assay, Reducing power assay and in vitro lipid peroxidation assay. 
A lower value IC50 observed for aqueous extract of PV (195 µg/ml ) in  Nitric oxide 
scavenging assay compared to that of the ethanolic extract (651 µg/ml ) indicates  the 
antioxidant potential possessed by the aqueous extract is greater than that of its ethanolic 
counterpart. However the antioxidant efficacy of the aqueous extract is lower than that of the 
standard Ascorbic Acid (IC50-98.26 µg/ml).  (Table No: 5) 
Reducing power assay is also performed to evaluate the antioxidant activity of the 
extracts. In this method, higher absorbance values obtained with the reaction mixtures denote 
higher reductive potential of the testing substance. Reducing power is considered a 
significant index of the antioxidant activity as the molecules with good reducing power are 
electron donors and can reduce the oxidized intermediates of lipid peroxidation processes and 
thus as primary and secondary antioxidants.[72] The observations in the present model also 
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demonstrate the greater antioxidant potential of the aqueous extract compared to the ethanolic 
extract. As the concentration of the testing substance increases the reducing power also was 
found to increase.  (Table No: 6) 
Lipid peroxidation involves the formation and propagation of lipid radicals, which 
eventually destroy membrane lipids. Oxidative stress in cells and tissues can be best 
monitored by its lipid peroxidation assay. The TBARS formation assay was used to assess the 
inhibition of Fe2+-induced lipid peroxidation by the extract.  In Lipid peroxidation assay the 
percentage of  inhibition and IC50 value are calculated. In lipid peroxidation inhibition assay, 
the plant extract inhibits the FeSO4 induced lipid peroxidation in egg yolk, which is the net 
result of iron-mediated hydroxyl radicals. This can be achieved either by scavenging the 
hydroxyl radicals or by chelating the iron ions, which is responsible for initiation of Fenton’s 
reaction.[73]  
 IC50 value of Standard Ascorbic Acid in lipid peroxidation assay was found to be 
171.66 µg/ml.  Both extracts showed a very good concentration-dependent inhibition of lipid 
peroxidation and almost equal activity (IC50 of aqueous and ethanolic extracts -732.33 
µg/ml, 700.66 µg/ml respectively). (Table No: 7).   
Impaired protection against oxidative stress resulted in calcium oxalate crystal 
deposition in kidney and treatment with antioxidants prevent this CaOx deposition. [25] Also 
Earlier studies report that membrane lipid peroxidation caused by high levels of calcium 
oxalate crystals induces cellular injury. [76] Possession of antioxidant activity implies that the 
extracts will prevent the calcium oxalate deposition in the kidney.[77]  
The polyphenols, tannins, content of the extracts have been reported to have metal 
chelating and hydroxyl radical scavenging properties. [9] 
Anti urolithiatic activity:  
Ethylene glycol and ammonium chloride are always used as urolithiasis induction 
agents because they induce Calcium oxalate crystalluria without severe renal damage in rats 
and they mimic the etiology of stone formation in human. [33] 
 Ammonium chloride causes acidification of urine consequently decreasing the citrate 
excretion in urine. This, in turn, increases the deposition of renal Calcium oxalate crystals 
and accelerates the Lithiasis. Induction of Calcium oxalate type of urolithiasis by Ethylene 
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glycol is a well-validated and clinically relevant model. Ethylene glycol is metabolized to 
form acidic metabolites such as oxalic acid, benzoic acid, formic acid, and hippuric acid, 
which causes metabolic acidosis. Subsequently, this acidic condition favours Calcium oxalate 
nucleation followed by growth, aggregation and crystallization, then finally retention at the 
renal tissue to cause renal mitochondrial toxicity similar to clinical Calcium oxalate renal 
calculi. [19] 
On administration of Ethylene glycol and Ammonium chloride in drinking water for 
15 days, a significant increase in the deposition of calcium and oxalate levels in the kidney 
were observed in both the preventive-control (Lithiatic) and curative-control (Lithiatic) 
groups when compared to the normal.  
  In the preventive regimen, animals treated with cystone and AEPV and EEPV at 
doses 200 and 400 mg/ kg, a significant decrease in calcium (p<0.05) and oxalate levels in 
urine was observed when compared to the preventive-control group (Lithiatic). In the 
curative regimen, animals treated with cystone and AEPV and EEPV also showed a 
significant(p<0.05, p<0.01) decrease in calcium and oxalate deposition in the kidney when 
compared to curative-control group (Lithiatic). These effects were found to be dose-
dependent. 
  Urine volume also played a major role in the Calcium oxalate stone formation. In this 
study, a decrease in urine output was observed in both preventive-control group (Lithiatic) 
and curative-control group (Lithiatic), indicating an obstruction in the urinary flow due to the 
presence of the Calcium oxalate stones. An increase in the urinary output was observed on 
treatment with EEPV and AEPV, indicating its diuretic action. Further, it dilutes the urinary 
electrolytes concentration and might decrease the chance of stone development. [31] 
An increase in urinary phosphate excretion was observed in both the preventive-
control (Lithiatic) and curative-control (Lithiatic) groups when compared to the normal. 
Elevated urinary phosphate excretion along with oxalate induced stress appears to provide a 
suitable environment for stone formation by forming calcium phosphate crystals, which  
causes Calcium oxalate deposition. Treatment with standard (cystone) and the plant extract 
treated (EEPV and AEPV) lowered the excretion of phosphate and reduced the risk of stone 
formation. 
 Discussion 
Dept of Pharmacology, Ultra College of Pharmacy.      Page 95 
Supersaturation is the step that occurs due to the presence of substances producing the 
kidney stones in high concentration in the urine following the decrement of urine volume and 
the concentration of chemicals that inhibit stone formation. [29] In our study the magnesium 
level in urine showed a significant decrease in urolithiatc group upon administration of 
ethylene glycol when compared to control group, the increase in urine magnesium level was 
recovered in animals that treated by standard (cystone) and the plant extract treated (EEPV 
and AEPV).   
In urolithiasis, there is a decrease in the glomerular filtration due to the obstruction of 
urine flow by stones in urinary system. This causes impairment of renal function resulting in 
decreased excretion of waste products, particularly nitrogenous substances such as Urea, 
Creatinine, and BUN with concurrent accumulation in blood. In the present study 
administration of Ethylene glycol with Ammonium chloride showed a significant elevation in 
serum Creatinine, Urea and BUN  excretion was observed in both the the preventive-control 
(Lithiatic) and curative-control (Lithiatic) groups when compared to the normal  group which 
indicates the marked renal damage. It was accompanied by the decreased glomerular 
filtration rate (GFR) due to obstruction of stones in the Bowman’s capsule. However, 
treatment of rats with standard (cystone) and the plant extract treated (AEPV and EEPV) 
show decreased serum Creatinine, Urea and BUN through improved glomerular filtration 
rate.  
An in vitro study suggests that phytic acid process anti-crystallization property by its 
chelating nature with the calcium. Phaseolus vulgaris beans are rich in phytic acid, which 
combines with calcium to form calcium-phytate complex that reduces the availability of 
calcium for stone formation by reducing its intestinal absorption. [9]  
Histopathological study:    
These results supported by our histopathological study that showed extensive vacuolar 
degeneration of renal tubular epithelium with presence of Calcium oxalate crystals in the 
lumen of dilated renal tubules in ethylene glycol group while the treatment of rats with 
standard (cystone)  plant extracts(AEPV and EEPV) reduced histopathological alterations 
The standard treated groups showed normal histology of the kidney, and shows 
normal glomeruli, slight oedema of the tubular cells. The AEPV & EEPV treated animals 
also showed the recovery 
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Kidneys of normal rats showed normal renal glomeruli and tubules with no evidence of 
tubular degeneration, dilatation or inflammatory reaction. Meanwhile, characteristic 
histopathological alterations were demonstrated in the Lithiatic control group represented by 
extensive vacuolar degeneration of renal tubular epithelium and presence of Calcium oxalate 
crystals in the lumen of renal tubules which are greatly dilated. In preventive study marked 
improvement of the histopathological alterations was demonstrated in Cystone and plant 
extract treated (AEPV and EEPV) group manifested by absence of inflammatory reaction, 
mild tubular degeneration and decreased number of renal tubules containing calculi. On the 
other hand, Curative treatment with plant extract treated (AEPV and EEPV) group showed 
the mild improvement represented by vacuolar degeneration of renal tubules and presence of 
Calcium oxalate crystals in the lumina of some renal tubules. 
The Antioxidant activity as well as the antiurolithiatic activity of the extracts can be 
attributed to the presence of the phytoconstituents flavonoids, polyphenols, tannins, and 
saponins because plant flavonoids are reported to possess antiurolithiatic activity through its 
antioxidant property.[77] The findings of other studies reveal that saponins have  
antiurolithiatic activity through its diuretic action and their ability in disaggregating the 
suspension of mucoproteins . 
The mechanism of the antiurolithiatic activity of the aqueous and ethanolic extracts of 
Phaseolus vulgaris may be through their potential of lowering stone forming constituents and 
by their antioxidant property. In future this study can be extended to perform bioactivity 
guided fractionation and to isolate the active principles responsible for the antiurolithiatic 
activity of phaseolus Vulgaris & and to probe the mechanisms of action.  
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 CONCLUSIONS  
The results of the present investigation on the evaluation of antiurolithiatic activity of 
aqueous and ethanolic extracts in rat models of preventive and curative lithiasis have led to 
the following conclusions. 
 
 In preventive and curative studies of AEPV and EEPV showed significant reduction in 
calcium, oxalate and phosphate levels in urine & an increase in the urinary magnesium 
and a restoration of normal urine volume. Serum levels of creatinine, uric acid and 
BUN were also brought down to normal values by the extracts. Histopathological 
observations also confirm the same. These findings indicate the potential of the 
extracts in inhibiting kidney stone formation as well as a lithotripsic action on the 
formed renal stones. 
 Aqueous extract is more potent than the ethanolic extract in the urolithiasis rat models.  
 The promising antioxidant activity of the extracts as revealed by in vitro nitric oxide 
scavenging assay, reducing power assay and in vitro lipid peroxidation study would 
have contributed to the antiurolithiatic activity of the extracts 
 Flavonoids, Polyphenols and saponins present in the extracts may be responsible of the 
antioxidant and antilithiatic activity of the extracts 
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